CA2199079A1 - Blends of absorbable polyoxaamides - Google Patents
Blends of absorbable polyoxaamidesInfo
- Publication number
- CA2199079A1 CA2199079A1 CA002199079A CA2199079A CA2199079A1 CA 2199079 A1 CA2199079 A1 CA 2199079A1 CA 002199079 A CA002199079 A CA 002199079A CA 2199079 A CA2199079 A CA 2199079A CA 2199079 A1 CA2199079 A1 CA 2199079A1
- Authority
- CA
- Canada
- Prior art keywords
- integer
- range
- group
- formula
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/44—Polyester-amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/105—Polyesters not covered by A61L17/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/049—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/668—Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/672—Dicarboxylic acids and dihydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/40—Polyamides containing oxygen in the form of ether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
- C08L67/025—Polyesters derived from dicarboxylic acids and dihydroxy compounds containing polyether sequences
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
- C08L77/12—Polyester-amides
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D167/00—Coating compositions based on polyesters obtained by reactions forming a carboxylic ester link in the main chain; Coating compositions based on derivatives of such polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
- Y10T428/1355—Elemental metal containing [e.g., substrate, foil, film, coating, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
- Y10T428/1362—Textile, fabric, cloth, or pile containing [e.g., web, net, woven, knitted, mesh, nonwoven, matted, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/24—Structurally defined web or sheet [e.g., overall dimension, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
- Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2904—Staple length fiber
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2933—Coated or with bond, impregnation or core
- Y10T428/294—Coated or with bond, impregnation or core including metal or compound thereof [excluding glass, ceramic and asbestos]
- Y10T428/2942—Plural coatings
- Y10T428/2947—Synthetic resin or polymer in plural coatings, each of different type
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31551—Of polyamidoester [polyurethane, polyisocyanate, polycarbamate, etc.]
Abstract
The present invention describes an aliphatic polyoxaamide polymer and blends thereof that may be used to produce surgical devices such as sutures, sutures with attached needles, molded devices, and the like. The aliphatic polyoxaamide of the present invention have a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, I
[-O-R5-C(O)-]B, and III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided both X and Y are not both -O- and may be blended with a second polymer that is preferably biocompatable.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, I
[-O-R5-C(O)-]B, and III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided both X and Y are not both -O- and may be blended with a second polymer that is preferably biocompatable.
Description
~ ~9~79 BLENDS CONTAINING ABSO~R~RT.~ POLYOXAAMIDES
Field Of The Invention The present invention relates to a polymeric material and more particularly to absorbable products made from polyoxaamides and blends thereof with other polymers.
Back~round of the Invention Since Carothers early ~ork in the 1920s and 1930s, aromatic polyester particularly poly(ethylene terephthalate) have become the most commercial important polyesters. The usefulness of these polymers is intimately linked to the stiffening action of the p-phenylene group in the polymer chain. The presence of the p-phenylene group in the backbone of the polymer chain leads to high melting points and good mPch~nical properties especially for fibers, films and some molded products. In fact poly(ethylene terephthalate) has become the polymer of choice for many common consumer products, such as one and two liter soft drink containers.
Several related polyester resins have been described in U.S. Patents 4,440,922, 4,552,948 and 4,963,641 which seek to improve upon the properties of poly(ethylene terephthalate) by replacing terephthalic acid with other . CA 02199079 1997-03-04 ~ 2 ~ 9~ a 7 9 related dicarboxylic acids which contain phenylene groups.
These polymers are generally designed to reduce the gas permeability of aromatic polyesters.
Other aromatic polyesters have also been developed for specialty applications such as radiation stable bioabsorbable materials. U.S. Patents 4,510,295, 4,546,152 and 4,689,424 describe radiation sterilizable aromatic polyesters which can be used to make sutures and the like. These polymers like, poly(ethylene terephthalate), have phenylene groups in the backbone of the polymers.
However, less research has been reported on aliphatic polyesters. After Carothers initial work on polyesters, aliphatic polyesters were generally ignored because it was believed that these materials had low melting points and high solubilities. The only aliphatic polyesters that have been extensively studied are polylactones such as polylactide, polyglycolide, poly(p-dioxanone) and polycaprolactone. These ~lirh~tic polylactones have been used primarily for bioabsorbable surgical sutures and surgical devices such as staples. Although polylactones have proven to be useful in many applications they do not meet all the needs of the medical community. For example films of polylactones do not readily transmit water vapor, therefore, are not ideally suited for use as bandages where the transmission of water vapor would be desired.
Only recently has there been renewed interest in non-lactone aliphatic polyesters. U.S. Patent 5,349,028 describes the formation of very simple aliphatic polyesters based on the reaction of a diol with a dicarboxylic acid to form prepolymer chains that are then i~ 2 .
coupled together. These polyesters are being promoted for use in fibers and molded articles because these polyesters are biodegradable after they are buried such as in a landf ill . However, these materials are not disclosed as 5 being suitable f or use in surgical devices .
Thus it is an obj ect of the present invention to provide aliphatic polyoxaamides (which includes polyoxaesteramides) and blends thereof with other polymers 10 that may be used in surgical devices such as ~uL~l~es, molded devices, drug delivery matrices, coatings, lubricants and the l ike .
Summar~ of the Invention We have discovered a new class of synthetic polyoxaamides and blends thereof with other polymers that may be used to produce a variety of useful products including surgical devices such as sutures, sutures with attached ne~l 1 PC, 20 molded devices, drug delivery matrices, coatings, lubricants and the like. The aliphatic polyoxaamides of the present invention are polymers comprising a f irst divalent repeating unit of f ormula I:
25tX-C(0)-C(RI) (R2)-0-(R3)-0-C(RI) (R2)-C(0)-3 and a secsn~ repeating unit selected from the group of formulas consisting of:
t-Y-RI7-3T~ II
[ ~~~Rs~C ( 0 ) ~ 3 E~
(~--0-Rg-C(o)]p-o--)LG XI
. CA 02199079 1997-03-04 and combinations thereof, wherein X and Y are selected from the group consisting of -0- and -N(R)-, provided that X and Y cannot both be -0-; R, R~ and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing l to 8 car~on atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D- (CH2)e~ IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to about 12; Rl7 is a alkylene unit contAining from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(RIB)- or an internal -C(0)-N(R2l)-; T is an integer in the range of from l to about 2,000 and preferably is in the range of from l to about l,000; Rlt and R2l are in~Pp~n~ntly selected from the group consisting of hyd~G~en and an alkyl group containing l to 8 carbon atoms; Rs and ~ are selected from the group consisting of -C(}~6)(R7)-, -(CH2) 3-O-, -CH2--CH2-O-CH2-, -CR~H-CH2-, (C~I2)4-, -(CH2)p-O-C(O)- and -(CH2)K-C(0)-CH2-; R6 and R7 are inAep~n~ntly selected from the group consisting of hyd~o~en and an alkyl containing from l to 8 carbon atoms;
R~ is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from l to n such that the number average molecular weight of formula III is less than about 200,000, preferably less than lO0,000 and more preferably less than 40,000; P is an integer in the range of from l to m such that the number . CA 02199079 1997-03-04 average molecular weight of formula XI is less than about l,000,000, preferably less than 200,000 and more preferably less than 40,000; G represents the residue minus from l to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from l to about 200 hydroxyl groups; and L is an integer from about l to about 200.
Detailed Descri~tion of the Invention The aliphatic polyoxaamides (which also includes polyoxaesteramides that are within the scope of the present invention) of the present invention are the reaction product of l) an aliphatic polyoxydicarboxylic acid and a diamine or amino alcohol optionally containing one of the following compounds: a diol (or polydiol), a lactone (or lactone oligomer), a coupling agent or combination thereof.
Suitable aliphatic alpha-oxydicarboxylic acids (or oxadicarboxylic acids) for use in the present invention generally have the following formula:
HO-C(O)-C(RI)(R2)-O-(R3)-O-C(Rl)(R2)-C(O)-OH V
wherein R, Rt and R2 are independently selected from the group consisting of hyd~o~en and an alkyl group containing from l to 8 carbon atoms and R3 is an alkylene containing from 2 to 12 carbon atoms or is an oxyalkylene group of the following formula:
-[(CH2)c-o-]D-(cH2)~- lV
wherein C is an integer in the range of from about 2 to ErH-1120 ~ 2 ~ 7 Q
about 5, D is an integer in the range of from 0 to about 2,000 and preferably 1 to about 12, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12. These aliphatic alpha-oxydicarboxylic acids may be formed by reacting a diol or polydiol with an alpha-halocarboxylic acid such bromoacetic acid or chloroacetic acid under suitable conditions.
Suitable amino alcohols, diamines, diols or polydiols for use in the present invention have repeating units with up to 8 carbon atoms having the formulas:
H[-(N(RI2)-RI3-)U]OH VIA
Ht-(N(RI4)-Rl5-)vN(Rl6) VIB
H~-(O-~-)A]OH, VIC
Ht-(O-RI9-)z]N(R2o)H~ VID
wherein R~3, R~5, ~ and R~9 are independently alkylene units cont~ini~ from 2 to 8 methylene units which may have substituted therein an internal ether oxygen, an internal -N(RI~)- or internal -C(O)-N(R2~)-; R~ and ~ are i~P~n~ntly selected from the group consisting of hyd~Gyen and an alkyl group containing 1 to 8 carbon atoms; R~2, R~4, R~6 and R~ are independently selected from the group consisting of hydrogen, alkyl group containing from 1 to 8 carbon atoms and mixtures thereof; A, U, V and Z are independently integers in the range of from 1 to about 2,000 and preferably from 1 to 1,000. Examples of suitable amino alcohols include amino alcohols selected from the group consisting of ethanol amine, isopropanol amine, 3-amino-1-propanol, 4-amino-1-butanol, 4-amino-2-butanol, 2-amino-1-butanol and 2-(2-aminoethoxy)ethanoI.
Examples of suitable diamines include d i~m i nes selected 7 ~
from the group consisting of ethylene diamine, 1,2-diaminopropane, 1,3-diaminopropane, 1,4-diaminobutane, 1,4-diaminocyclohexane and 1,S-diamino-3-oxapentane.
Examples of suitable diols include diols selected from the group consisting of 1,2-ethanediol (ethylene glycol), 1,2-propanediol (propylene glycol), 1,3-propanediol, 1,4-butanediol, 1,S-pentanediol, 1,3-cyclopentanediol, 1,6-hexanediol, 1,4-cyclohexanediol, 1,8-octanediol and combinations thereof. Examples of preferred polydiols include polydiols selected from the group consisting of polyethylene glycol (H[-O-CH2-CH2-]~OH) and pol~Lo~ylene glycol (H[-O-CH2-CH(CH3)-]~OH).
The polymer produced by reacting the aliphatic dioxacarboxylic acid with the amino alcohols discllcc~
above should provide a polymer generally having the formula:
t-O-C(O)-C(RI)(R2)-O-(R3)-O-C(R~)(R2)-C(O)-(N(RI2)-RI3)u~]l VIIA
wherein Rl, R2, R3, Rl2, Rl3 and U are as described above; and J is an integer in the range of from about 1 to about 10,000 and preferably is in the range of from about 10 to about 1,000 and most preferably in the range of from about SO to about 200.
The polymer produced by reacting the aliphatic dioxacarboxylic acid with the diamine discussed above should provide a polymer generally having the formula:
t-N(RI6)-C(O)-C(RI) (R2)-O-(R3)-O-C(RI) (R2)-c(o)-(N(Rl4)-Rl5)v-]J
VIIB
wherein Rl, R2, R3, Rl4, Rl5, Rl6 V and J are as described above.
Q ~ 9 .
The polymer produced by reacting the aliphatic dioxacarboxylic acid with a mixture of aminoalcohols, diols and diamines discussed above should provide a polymer generally having end groups that may be active amines or hydroxyl groups.
Suitable lactone monomers that may be used in the present invention generally have the formula:
~0-R~-C(0)~ VDI
These lactone monomers (or equivalent acids if any) may be polymerized to provide polymers of the following general structures:
Ht-O~R5~c(0)-3soH IX
(Ht ~O~Rg~C (O) ] p-O-) LG X
wherein ~ and ~ are independently selected from the group consisting of -C(~)(~)-, -(CH2)3-0-, -CH2-CH2-0-CH2-, -C~H-CH2-~ -(CH2)4-~ -(C~)p-O-c(O)- and -(CH2)K-C(O)-CH2-; R6 and ~ are i~p~nAently selected from the group consisting of l.yd~G~en and an alkyl containing from l to 8 carbon atoms;
~ is selected from the group consisting of hydrogen and methyl; F and K are integers in the range of from 2 to 6;
B is an integer in the range of from l to n such that the number average molecular weight of formula IX is less than about 200,000, preferably less than about lO0,000, more preferably less than about 40,000 and most preferably less than 20,000; P is an integer in the range of from l to m such that the number average molecular weight of formula X is less than about l,OOO,Ooo, preferably less than about ~ 2 ~ 7 ~
g 200,000, more preferably less than about 40,000 and most preferably less than 20,000; G represents the residue minus from l to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from l to about 200 hydroxyl groups; and L is an integer from about l to about 200. Preferably G will be the residue of a dihydroxy alcohol minus both hydroxyl groups. Suitable lactone-derived repeatinq units may be generated from the following monomers include but are not limited to lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, meso-lactide, ~-caprolactone, p-dioxanone, trimethylene carbonate, l,4-dioxepan-2-one, l,5-dioxepan-2-one and combinations thereof.
The polymer formed by reacting the above described amino alcohols, diamines, and diol (or polydiol) VI with the appropriate aliphatic oxadicarboxylic acid or aliphatic polyoxydicarboxylic acid V may also be copolymerized in a ~on~ry ring-opening polymerization with the lactone monomers XIII or in a con~P~c~tion copolymerization with the lactone oligomers IX or X, described above to form a polymer generally of the formula:
t(-C(O)-C(R~)(R2)-O-R3-O-C(RI)(R2)-C(O)-(Y-R4)~-X)s~
~(C(O)-Rs-o)s]w XII
or t(-C(O)-C(RI)(R2)-O-R3-O-C(Rl)(R2)-C(O)-(Y-~) A X) 5 -(~-O-~-c(o)]p-o-)LG~w XIII
30 wherein X and Y are selected from the group consisting of -O- and N(R), provided that X and Y cannot both be -O-;
and S is an integer in the range of from about l to about lO,000 and is preferably an integer in the range of from about l to about l,000 and W is an integer in the range of ErH-1120 ~ ~ ~ Q~ a 7 9 from about 1 to about 1,000. These polymers may be made in the form of random copolymers or block copolymers. To the compounds described above there may be added a coupling agent selected from the group consisting of trifunctional or tetrafunctional polyols, oxycarboxylic acids, and polybasic carboxylic acids (or acid anhydrides thereof). The addition of the coupling agents causes the br~hing of long chains, which can impart desirable properties in the molten state to the polyester prepolymer. Examples of suitable polyfunctional coupling agents include trimethylol propane, glycerin, pentaerythritol, malic acid, citric acid, tartaric acid, trimesic acid, propane tricarboxylic acid, cyclopentane tetracarboxylic anhydride, triethanol amine and combinations thereof.
The amount of coupling agent to be added before gelation O~lS is a function of the type of coupling agent used and the polymerization conditions of the polyoxaamide or 20 molec~ r weight of the prepolymer to which it is added.
Generally in the range of from about 0.1 to about 10 mole percent of a trifunctional or a tetrafunctional coupling agent may be added based on the moles of aliphatic polyoxaamide polymers present or anticipated from the synthesis.
The preparation of the aliphatic polyoxaamides (which also includes polyoxaesteramides) are preferably polymerizations performed under melt polycondensation conditions at elevated temperatures. At times it may be preferably to add a catalyst such as an organometallic compound. Preferred organometallic catalysts are tin-based catalysts e.g. stannous octoate. The catalyst will preferably be present in the mixture at a mole ratio ~ ~ ~ 9 ~ ~ 7 ~
of hydroxy groups, aliphatic polyoxydicarboxylic acid and optionally lactone monomer to catalyst will be in the range of from about 5,000 to about 80,000/1. The reaction is preferably performed at a temperature no less than about 120~C under reduced pressure. Higher polymerization temperatures may lead to further increases in the molecular weight of the copolymer, which may be desirable for numerous applications.
The exact reaction conditions chosen will depend on numerous factors, including the properties of the polymer desired, the viscosity of the reaction mixture, and the glass transition temperature and softening temperature of the polymer. The preferred reaction conditions of temperature, time and pressure can be readily determined by assessing these and other factors.
Generally, the reaction mixture will be maintained at about 220~C. The polymerization reaction can be allowed to proceed at this temperature until the desired mol~c~lAr weight and percent conversion is achieved for the copolymer, which will typically take about lS minutes to 24 hours. Increasing the reaction temperature generally decreases the reaction time needed to achieve a particular molecular weight, but may also increase the extent of side reactions. We have found that reaction at about 220-C to be generally suitable.
In another emho~ment, aliphatic polyoxaamide copolymers can be prepared by forming an aliphatic polyoxaamide prepolymer polymerized under melt polycondensation conditions, then adding at least one lactone monomer or lactone prepolymer. The mixture would then be subjected to the desired conditions of temperature and time to copolymerize the prepolymer with the lactone monomers. If ErH-1120 - -a lactone prepolymer is used, a polycondensation reaction can be used to increase the molecular weight.
The molecular weight of the prepolymer as well as its composition can be varied depending on the desired characteristic which the prepolymer is to impart to the copolymer. However, it is preferred that the aliphatic polyoxaamide prepolymers from which the copolymer is prepared have a molecular weight that provides an inherent viscosity between about 0.2 to about 2.0 deciliters per gram (dl/g) as measured in a 0.l g/dl solution of hexafluoroisopropanol at 25~C. Those skilled in the art will recognize that the aliphatic polyoxaamide prepolymers described herein can also be made from mix~u~es of more than one diol, amino alcohol, or dioxacarboxylic acid.
One of the beneficial properties of the aliphatic polyoxaamide made by the process of this invention is that the ester linkages are hydrolytically unstable, and therefore the polymer is bioabsorbable because it readily breaks down into small segments when exposed to moist bodily tissue. In this regard, while it is envisioned that co-reactants could be incorporated into the reaction mixture of the aliphatic dioxacarboxylic acid and the diol for the formation of the aliphatic polyoxaamide prepolymer, it is preferable that the reaction mixture does not contain a concentration of any co-reactant which would render the subsequently prepared polymer non~h~Qrbable. Preferably, the reaction mixture is substantially free of any such co-reactants if the resulting polymer is rendered nonabsorbable.
These aliphatic polyoxaamides of the present invention and those described in Serial No. 08/399,308, filed March 6, ErH-1120 1995 and assigned to Ethicon, now U.S. Patent No.
5,464,929 may be blended together with other homopolymers copolymers and graft copolymers to impart new properties to the material formed by the blend. The other polymers which the aliphatic polyoxaamides may be blended with include but are not limited to homopolymer and copolymer of lactone type polymers with the repeating units described by Formula VIII, polyesters (such as adipates) aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers (such as ethylene-vinyl acetate copolymers and ethylene ethyl acrylate copolymers), polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate). The copolymers (i.e. containing two or more repeating units) including random, block and segmented copolymers. Suitable lactone-derived repeating units may be generated from the following monomers include but are not limited to lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, meso-lactide, ~-caprolactone, p-dioxanone, trimethylene carbonate, l,4-dioxepan-2-one, l,5-dioxepan-2-one and combinations thereof. The blends may contain about l weight percent to about 99 weight percent of the aliphatic polyoxaamides.
For some applications it may be desirable to add additional ingredients such as stabilizers, antioxidants radiopacifiers, fillers or the like.
The aliphatic polyoxaamide and other polymers may be blended using conventional mixing processes known in the art. For example a blend can be prepared using a two-roll ErH-1120 ~ 2 ~ Q7 ~
mill, an internal mixer (such as a Brabender or Banbury mixer), an extruder (such as a twin screw extruder) or the like.
The polymer blends of this invention can be melt processed by numerous methods to prepare a vast array of useful devices. These polymer blends can be injection or compression molded to make implantable medical and surgical devices, especially wound closure devices. The preferred wound closure devices are surgical clips, staples and sutures.
Alternatively, the polymer blends can be extruded to prepare fibers. The filaments thus produced may be fabricated into sutures or ligatures, attached to surgical needles, packaged, and sterilized by known tec~n;ques.
The polymers of the present invention may be spun as multifilament yarn and woven or knitted to form sponges or gauze, (or non-woven sheets may be prepared) or used in conjunction with other molded compressive structures as prosthetic devices within the body of a human or animal where it is desirable that the structure have high tensile strength and desirable levels of compliance and/or ductility. Useful embodiments include tubes, including brAnc~e~ tubes, for artery, vein or intestinal repair, nerve splicing, tendon splicing, sheets for typing up and --u~o~ing damaged surface abrasions, particularly major abrasions, or areas where the skin and underlying tissues are damaged or surgically removed.
Additionally, the polymer blends can be molded to form films which, when sterilized, are useful ~s adhesion prevention barriers. Another alternative processing tech~i~ue for the polymer blends of this invention ErH-1120 7 ~
includes solvent casting, particularly for those applications where a drug delivery matrix is desired.
In more detail, the surgical and medical uses of the filaments, films, and molded articles of the present invention include, but are not necessarily limited to:
Knitted products, woven or non-woven, and molded products including:
a. burn dressings b. hernia patches c. medicated dressings d. fascial substitutes e. gauze, fabric, sheet, felt or sponge for liver hemostasis f. gauze bandages g. arterial graft or substitutes h. bandages for skin surfaces i. ~uL~e knot clip j. or~hop~ic pins, clamps, screws, and plates k. clips (e.g.,for vena cava) l. staples m. hooks, buttons, and snaps n. bone substitutes (e.g., mandible prosthesis) o. intrauterine devices (e.g.,spermicidal devices) p. draining or testing tubes or capillaries q. surgical instruments r. vA~ 1Ar implants or supports s. vertebral discs t. extracorporeal tubing for kidney and heart-lung machines u. artificial skin and others v. catheters (including, but not limi~e3 to, the catheters described in U.S. Patent No. 4,883,699 ErH-1120 -- O ~ ~9 Q7 ~
which is hereby incorporated by reference) w. scaffoldings and the like for tissue engineering applications.
In another embodiment, the polymer blends can be used to coat a surface of a surgical article to enhance the lubricity of the coated surface. The polymer blends may be applied as a coating using conventional techniques.
For example, the polymer blends may be solubilized in a dilute solution of a volatile organic solvent, e.g.
acetone, methanol, ethyl acetate or toluene, and then the article can be immersed in the solution to coat its surface. Once the surface is coated, the surgical article can be removed from the solution where it can be dried at room or elevated temperatures until the solvent and any residual reactants are removed.
For use in coating applications the polymer blends should exhibit an inherent viscosity, as measured in a 0.l gram per deciliter (g/dl) of hexafluoroisopropanol (HFIP), between about 0.05 to about 2.0 dl/g, preferably about 0.l0 to about 0.80 dl/g. If the inherent viscosity were less than about 0.05 dl/g, then the polymer blends may not have the integrity nereCs~ry for the preparation of films or coatings for the surfaces of various surgical and medical articles. On the other hand, although it is possible to use polymer blends with an inherent viscosity greater than about 2.0 dl/g, it may be exr~e~ingly difficult to do so.
Although it is contemplated that numerous surgical articles (including but not limited to endoscopic instruments) can be coated with the polymer blends of this invention to improve the surface properties of the article, the preferred surgical articles are surgical sutures and needles. The most preferred surgical article is a suture, most preferably attached to a needle.
Preferably, the suture is a synthetic absorbable suture.
These ~uLuLes are derived, for example, from homopolymers and copolymers of lactone monomers such as glycolide, lactide, ~-caprolactone, l,4-dioxanone, and trimethylene carbonate. The preferred suture is a braided multifilament suture composed of polyglycolide or poly(glycolide-co-lactide).
The amount of polymer blend to be applied on the surface of a braided suture can be readily determined empirically, and will depend on the particular copolymer and ~uLule 5 ~h9c~. Ideally, the amount of polymer blend applied to the surface of the suture may range from about 0.5 to about 30 percent of the weight of the coated ~uL~e, more preferably from about l.0 to about 20 weight percent, most preferably from l to about 5 weight percent. If the amount of coating on the suture were greater than about 30 weight percent, then it may increase the risk that the coating may flake off when the suture is pacsed through tissue.
Sutures coated with the polymer blends of this invention are desirable because they have a more slippery feel, thus making it easier for the surgeon to slide a knot down the ~uL~e to the site of surgical trauma. In addition, the ~uLu~e can be p~qe~ more easily through body tissue thus reducing tissue trauma. These advantages are exhibited in comparison to sutures which do not have their surfaces coated with the polymer blends of this invention.
In another embodiment of the present invention when the 7 ~
article is a surgical needle, the amount of coating applied to the surface of the article is an amount which creates a layer with a thickness ranging prefera~ly between about 2 to about 20 microns on the needle, more preferably about 4 to about 8 microns. If the amount of coating on the needle were such that the thickness of the coating layer was greater than about 20 microns, or if the thickness was less than about 2 microns, then the desired performance of the needle as it is passed through tissue may not be achieved.
In another embodiment of the present invention, the polymer blends can be used as a pharmaceutical carrier in a drug delivery matrix. To form this matrix the polymer blends would be mixed with a therapeutic agent to form the matrix. The variety of different therapeutic agents which can be used in conjunction with the polymer blends of the present invention is vast. In general, therapeutic agents which may be administered via the pharmaceutical compositions of the invention include, without limitation:
antiinfectives such as antibiotics and antiviral agents;
analgesics and analgesic combinations; anorexics;
antihelmintics; antiarthritics; antiasthmatic agents;
anticonvulsants; antidepressants; antidiuretic agents;
antidiarrheals; antihistamines; antiinflammatory agents;
antimigraine preparations; antinauseants; antineoplastics;
antiparkinsonism drugs; antipruritics; antipsychotics;
antipyretics, antispasmodics; anticholinergics;
sympathomimetics; xanthine derivatives; cardiovA~c~1Ar preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics;
antihypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including . CA 02199079 1997-03-04 7 ~
, decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics;
immunosuppressives; muscle relaxants; parasympatholytics;
psychostimulants; sedatives; and tranquilizers; and naturally derived or genetically engineered proteins, polysaccharides, glycoproteins, or lipoproteins.
The drug delivery matrix may be administered in any suitable dosage form such as oral, parenteral, a subcutaneously as an implant, vaginally or as a ~ ository. Matrix formulations containing the polymer blends may be formulated by mixing one or more therapeutic agents with the blends. The therapeutic agent, may be present as a liquid, a finely divided solid, or any other a~lo~}iate physical form. Typically, but optionally, the matrix will include one or more additives, e.g., nontoxic auxiliary substances such as diluents, carriers, excipients, stabilizers or the like. Other suitable additives may be formulated with the blends and pharmaceutically active agent or compound, however, if water is to be used it should be added immediately before administration.
The amount of therapeutic agent will be dependent upon the particular drug employed and medical condition being treated. Typically, the amount of drug represents about 0.001% to about 70%, more typically about 0.001% to about 50%, most typically about 0.001% to about 20% by weight of the matrix.
The quantity and type of polymer blends incorporated into the parenteral will vary depending on the release profile desired and the amount of drug employed. The product may contain blends of polymers of different molecular weights ErH-1120 . CA 02199079 1997-03-04 7 ~
to provide the desired release profile or consistency to a given formulation.
The polymer blends, upon contact with body fluids including blood or the like, undergoes gradual degradation (mainly through hydrolysis) with concomitant release of the dispersed drug for a sustained or extended period (as compared to the release from an isotonic saline solution).
This can result in prolonged delivery (over, say l to 2,000 hours, preferably 2 to 800 hours) of effective amounts (say, O.OOOl mg/kg/hour to lO mg/kg/hour) of the drug. This dosage form can be administered as is neceeC~ry depending on the subject being treated, the severity of the affliction, the judgment of the prescribing physician, and the like.
Individual formulations of drugs and polyoxaamide may be tested in appropriate in vitro and in vivo models to achieve the desired drug release profileQ. For example, a drug could be formulated with a polyoxaamide and orally administered to an animal. The drug release profile could then be monitored by appropriate means such as, by ~i nq blood samples at specific times and assaying the samples for drug concPntration. Following this or similar ~e~1 ~es, those skilled in the art will be able to formulate a variety of formulations.
The polymers, copolymers and blends of the present invention can be crosslinked to affect mech~nical properties. Crosslinking can be accomplished by the addition of crosslinking ~h~ncers and/or irradiation (such as gamma-irradiation). In particular, crosslinking can be used to ~o"L~ol the water swellablity of said invention.
ErH-1120 In a further embodiment of the present invention the polyoxaamide polymers and polymer blends of the present invention can be used in tissue engineering applications as supports for cells. Appropriate tissue scaffolding structures are known in the art such as the prosthetic articular cartilage described in U.S. Patent 5,306,311, the porous biodegradable scaffolding described in WO 94/25079, and the prevascularized implants described in WO 93/08850. Methods of seeding and/or culturing cells in tissue scaffoldings are also known in the art such as those methods disclosed in EPO 422 209 Bl, WO 88/03785, WO 90/12604 and WO 95/33821.
The Examples set forth below are for illustration purposes only, and are not intended to limit the scope of the claimed invention in any way. Numerous additional embodiments within the scope and spirit of the invention will become readily apparent to those skilled in the art.
ExamPle 1 Preparat$on of 3,6-Diox~octanedioic acid and its dimethylester HO~_~-~o,~~_~O~_'~'OH HN~ ~ ~ OH
Tr. b'.JlPn~ glycol 3,6-r~ ' acid H+
O
~0~~~oa~
D~es~rof3.~. I e~cil The diacid, 3,6-dioxaoctanedioic acid, was syn~hesiz~ by oxidation of triethylene glycol. The oxidation was carried out in a 500 milliliter, three-neck round bottom flask equipped with a thermometer, an additional funnel, a gas absorption tube and a magnetic spinbar. The reaction flask was lowered into an oil bath resting upon a magnetic stirrer. To the reaction flask was added 157.3 ml of a 60%
nitric acid solution; 37.0 g of triethylene glycol was added to the additional funnel. The contents of the flask were heated to 78-80 C. A test tube containing 0.5 g of glycol and one milliliter of concentrated nitric acid was warmed in a water bath until brown fumes started appearing. The contents were then added to the reaction flask. The mixture was stirred for a few minutes; the glycol was then carefully added. The rate of addition had to be monitored extremely carefully to keep the reaction 7 ~
under control. The addition rate was slow enough so that the temperature of the exothermic reaction mixture was maintained at 78-82 C. After the addition was completed (80 minutes), the temperature of the reaction mixture was maintained at 78-80 C for an additional hour. While continuing to maintain this temperature range, the ~Ycecc nitric acid and water was then distilled off under re~llse~
pressure (water suction). The syrupy residue was cooled;
some solids appeared. The reaction product had the IR and 10 NMR spectra expected for the dicarboxylic acid; the crude product was used as such for esterification.
The crude diacid could be purified to the extent neP~e~
for polymerization or alternately could be converted to the co~e~ponding diester, the diester purified and ~ubsequently hydrolyzed back to (purified) diacid. In yet another mode of purification, the diamine salts of the diacids are purified and then subsequently polymerized to form the polyoxaamides of the present invention.
Esterification of the crude 3,6-dioxaoctanedioic acid was accomplished as follows: To the reaction flask cont~i~in~
36 g of the crude diacid, was added 110 ml of methanol.
This was stirred for 3 days at room temperature after which 15 g of sodium bicarbonate was added and stirred overnight. The mixture was filtered to remove solids. To the liquor was added an additional 10 g of sodium bicarbonate; this mixture was stirred overnight. The mixture was again filtered; the liquor was fractionally distilled. NMR analysis of the esterified product showed a mixture of dimethyl triglycolate (78.4 mole%) and monomethyltriglycolate (21.6 mole%). No significant con~Pn~tion of diacid was observed.
Q 7 ~
ExamPle 2 Preparation of polyoxaesteramide from 3,6-dioxaoctanedioic acid and ethanolamine ~~o~ ~~D'OH + HOCH2CH2NH2 3,6-diox~oct~nedioic acid ~O - ~O~Jl~N~
Polyoxaesteramides A flame dried, me~n;cally stirred, 50-milliliter glass reactor suitable for polycondensation reaction, is charged 20 with the equivalent of 0.1 mole of purified 3,6-dioxaoctanedioic acid from Example 1 (17.81g), and 0.1 mole of ethanolamine (6.11g). This generally could be done by charging the reactor with exact stoichometric amounts of the diacid and the amino alcohol; alternately 25 a small eYcecc of ethylene glycol can be substituted for a portion of the amino alcohol. The polymerization can be ~on~ltcted without additional catalyst or alternately a small amount of catalyst (eg. 0.0606 ml of a solution of 0.33M stannous octoate in toluene) can be added. After purging the reactor and venting with nitrogen, the temperature is gradually raised over the course of 26 hours to 180 C. A temperature of 180-C is then maintained for another 20 hours; all during these heating periods under nitrogen at one atmosphere, the water formed is collected. The reaction flask is allowed to cool to room temperature; it is then slowly heated under reduced pressure (0.015-1.0 mm) over the course of about 32 hours to 160-C, during which time additional distillates can be collected. A temperature of 160-C i5 maintained for 4 hours after which a sample, a few grams in size, of the polymer formed is taken. The sample is found to have an inherent viscosity (I.V.) of approximately 0.2 dl/g, as determined in hexaflouroisopropanol (HFIP) at 25 C at a concentration of 0.1 g/dl. The polymerization is continued under reduced pressure while raising the temperature, in the course of about 16 hours, from 160-C to 180-C; a temperature of 180-C is maintained for an additional 8 hours, at which time a polymer sample is taken and found to have an I.V. of approximately 0.3 dl/g. The reaction is contin-lP~ under reduced pressure for another 8 hours at 180-C. The resulting polymer should have an inherent viscosity of approximately 0.4 dl/g, as determined in HFIP
at 25-C and at a concentration of 0.1 g/dl.
7 ~
Example 3 Preparation of polyoxa~mide with 3,6,9-trioxaundecanedioic 5acid and ethylene diamine HO ~ ,~_,O~_,_~ ~ OH + H2NCH2CH2NH2 O O
3,6,~Trioxaundecanedioic acid ~f ~O ~o~N~~N~n O O
Polyoxaamides A flame dried, mechanically stirred, 250-milliliter glass reactor, suitable for polycondensation reaction, is charged with the equivalent of 0.2 mole (44.44 g) of 3,6,9-trioxaundecanedioic acid, and 0.2 mole (12.02 g) of ethylene diamine; this can be conveniently done by charging the reactor with the stoichometric salt formed between the diacid and the diamine. Alternately a small excess of ethylene glycol can be substituted for a portion of the diamine. The polymerization can be conducted without additional catalyst or alternately a small amount of catalyst (eg. 0.0606 ml of a solution of 0.33M stannous octoate in toluene or 10 milligrams of dibutyltin oxide) can be added.
After purging the reactor and venting with nitrogen, the contents of the reaction flask are gradually heated under nitrogen at one atmosphere, in the course of about 32 ErH-1120 . CA 02199079 1997-03-04 7 ~
hours, to 180 C, during which time the water formed is collected. The reaction mass is allowed to cool to room temperature. The reaction mass is then heated under reduced pressure (0.015-1.0 mm), gradually increasing the temperature to 180 C in about 40 hours; during this time additional distillates is collected. The polymerization is continued under reduced pressure while maintaining 180-C
for an additional 16 hours. The resulting polymer should have an inherent viscosity of approximately 0.5 dl/g as determined in HFIP at 25 C and at a concentration of 0.1 g/dl.
~xamDle 4 Proparation of polyoxaamide with polyglycol diacid and Jeffamine o HO~O~~Om~OH + H2N~Q~n~NH2 Polyglycol dlscld [m=1 1l J~mln~ [n=1 1l O
~~~m ~N~0~3~o~N}~
O H
P~ I s A flame dried, mechAnically stirred, 500-milliliter glass reactor (suitable for polycondensation reaction) i8 charged with the equivalent of 0.2 mole (123.8 g) of polyglycol diacid (molecular weight about 619), and 0.2 mole (117.7g) of Jeffamine (amine terminated polyethylene oxide). This generally could be done by charging the reactor with stoichometric amounts of the diac~d and the diamine or by charging the corresponding preformed salt of ErH-l120 the diacid and diamine. As an alternate process, a small excess of ethylene glycol can be substituted for a portion of the diamine. The polymerization can be conducted without additional catalyst or alternately a small amount of catalyst. After purging the reactor and venting with nitrogen, the contents of the reaction flask is heated under nitrogen at one atmosphere, gradually increasing the temperature to 200 C in about 32 hours; during this time the water formed is collected. The reaction flask is heated gradually under reduced pressure (O.OlS-1.0 mm) from room temperature to 140-C in about 24 hours, during which time additional distillates are collected. A polymer sample of about ten grams is taken at this stage, and found to have an I.V. of approximately 0.1 dl/g in HFIP at 25-C, 0.1 g/dl. The polymerization is continued under reduced pressure while heating from 140-C to 180-C in about 8 hours, and then maintained at 180-C for an additional 8 hours. The reaction temperature is then increased to l90 C and maintained there under re~l~c~
pressure for an additional 8 hours. The resulting polymer should have an inherent viscosity of approximately 0.6 dl/g as determined in HFIP at 25 C and at a concentration of 0.1 g/dl.
ErH-1120
Field Of The Invention The present invention relates to a polymeric material and more particularly to absorbable products made from polyoxaamides and blends thereof with other polymers.
Back~round of the Invention Since Carothers early ~ork in the 1920s and 1930s, aromatic polyester particularly poly(ethylene terephthalate) have become the most commercial important polyesters. The usefulness of these polymers is intimately linked to the stiffening action of the p-phenylene group in the polymer chain. The presence of the p-phenylene group in the backbone of the polymer chain leads to high melting points and good mPch~nical properties especially for fibers, films and some molded products. In fact poly(ethylene terephthalate) has become the polymer of choice for many common consumer products, such as one and two liter soft drink containers.
Several related polyester resins have been described in U.S. Patents 4,440,922, 4,552,948 and 4,963,641 which seek to improve upon the properties of poly(ethylene terephthalate) by replacing terephthalic acid with other . CA 02199079 1997-03-04 ~ 2 ~ 9~ a 7 9 related dicarboxylic acids which contain phenylene groups.
These polymers are generally designed to reduce the gas permeability of aromatic polyesters.
Other aromatic polyesters have also been developed for specialty applications such as radiation stable bioabsorbable materials. U.S. Patents 4,510,295, 4,546,152 and 4,689,424 describe radiation sterilizable aromatic polyesters which can be used to make sutures and the like. These polymers like, poly(ethylene terephthalate), have phenylene groups in the backbone of the polymers.
However, less research has been reported on aliphatic polyesters. After Carothers initial work on polyesters, aliphatic polyesters were generally ignored because it was believed that these materials had low melting points and high solubilities. The only aliphatic polyesters that have been extensively studied are polylactones such as polylactide, polyglycolide, poly(p-dioxanone) and polycaprolactone. These ~lirh~tic polylactones have been used primarily for bioabsorbable surgical sutures and surgical devices such as staples. Although polylactones have proven to be useful in many applications they do not meet all the needs of the medical community. For example films of polylactones do not readily transmit water vapor, therefore, are not ideally suited for use as bandages where the transmission of water vapor would be desired.
Only recently has there been renewed interest in non-lactone aliphatic polyesters. U.S. Patent 5,349,028 describes the formation of very simple aliphatic polyesters based on the reaction of a diol with a dicarboxylic acid to form prepolymer chains that are then i~ 2 .
coupled together. These polyesters are being promoted for use in fibers and molded articles because these polyesters are biodegradable after they are buried such as in a landf ill . However, these materials are not disclosed as 5 being suitable f or use in surgical devices .
Thus it is an obj ect of the present invention to provide aliphatic polyoxaamides (which includes polyoxaesteramides) and blends thereof with other polymers 10 that may be used in surgical devices such as ~uL~l~es, molded devices, drug delivery matrices, coatings, lubricants and the l ike .
Summar~ of the Invention We have discovered a new class of synthetic polyoxaamides and blends thereof with other polymers that may be used to produce a variety of useful products including surgical devices such as sutures, sutures with attached ne~l 1 PC, 20 molded devices, drug delivery matrices, coatings, lubricants and the like. The aliphatic polyoxaamides of the present invention are polymers comprising a f irst divalent repeating unit of f ormula I:
25tX-C(0)-C(RI) (R2)-0-(R3)-0-C(RI) (R2)-C(0)-3 and a secsn~ repeating unit selected from the group of formulas consisting of:
t-Y-RI7-3T~ II
[ ~~~Rs~C ( 0 ) ~ 3 E~
(~--0-Rg-C(o)]p-o--)LG XI
. CA 02199079 1997-03-04 and combinations thereof, wherein X and Y are selected from the group consisting of -0- and -N(R)-, provided that X and Y cannot both be -0-; R, R~ and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing l to 8 car~on atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D- (CH2)e~ IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to about 12; Rl7 is a alkylene unit contAining from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(RIB)- or an internal -C(0)-N(R2l)-; T is an integer in the range of from l to about 2,000 and preferably is in the range of from l to about l,000; Rlt and R2l are in~Pp~n~ntly selected from the group consisting of hyd~G~en and an alkyl group containing l to 8 carbon atoms; Rs and ~ are selected from the group consisting of -C(}~6)(R7)-, -(CH2) 3-O-, -CH2--CH2-O-CH2-, -CR~H-CH2-, (C~I2)4-, -(CH2)p-O-C(O)- and -(CH2)K-C(0)-CH2-; R6 and R7 are inAep~n~ntly selected from the group consisting of hyd~o~en and an alkyl containing from l to 8 carbon atoms;
R~ is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from l to n such that the number average molecular weight of formula III is less than about 200,000, preferably less than lO0,000 and more preferably less than 40,000; P is an integer in the range of from l to m such that the number . CA 02199079 1997-03-04 average molecular weight of formula XI is less than about l,000,000, preferably less than 200,000 and more preferably less than 40,000; G represents the residue minus from l to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from l to about 200 hydroxyl groups; and L is an integer from about l to about 200.
Detailed Descri~tion of the Invention The aliphatic polyoxaamides (which also includes polyoxaesteramides that are within the scope of the present invention) of the present invention are the reaction product of l) an aliphatic polyoxydicarboxylic acid and a diamine or amino alcohol optionally containing one of the following compounds: a diol (or polydiol), a lactone (or lactone oligomer), a coupling agent or combination thereof.
Suitable aliphatic alpha-oxydicarboxylic acids (or oxadicarboxylic acids) for use in the present invention generally have the following formula:
HO-C(O)-C(RI)(R2)-O-(R3)-O-C(Rl)(R2)-C(O)-OH V
wherein R, Rt and R2 are independently selected from the group consisting of hyd~o~en and an alkyl group containing from l to 8 carbon atoms and R3 is an alkylene containing from 2 to 12 carbon atoms or is an oxyalkylene group of the following formula:
-[(CH2)c-o-]D-(cH2)~- lV
wherein C is an integer in the range of from about 2 to ErH-1120 ~ 2 ~ 7 Q
about 5, D is an integer in the range of from 0 to about 2,000 and preferably 1 to about 12, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12. These aliphatic alpha-oxydicarboxylic acids may be formed by reacting a diol or polydiol with an alpha-halocarboxylic acid such bromoacetic acid or chloroacetic acid under suitable conditions.
Suitable amino alcohols, diamines, diols or polydiols for use in the present invention have repeating units with up to 8 carbon atoms having the formulas:
H[-(N(RI2)-RI3-)U]OH VIA
Ht-(N(RI4)-Rl5-)vN(Rl6) VIB
H~-(O-~-)A]OH, VIC
Ht-(O-RI9-)z]N(R2o)H~ VID
wherein R~3, R~5, ~ and R~9 are independently alkylene units cont~ini~ from 2 to 8 methylene units which may have substituted therein an internal ether oxygen, an internal -N(RI~)- or internal -C(O)-N(R2~)-; R~ and ~ are i~P~n~ntly selected from the group consisting of hyd~Gyen and an alkyl group containing 1 to 8 carbon atoms; R~2, R~4, R~6 and R~ are independently selected from the group consisting of hydrogen, alkyl group containing from 1 to 8 carbon atoms and mixtures thereof; A, U, V and Z are independently integers in the range of from 1 to about 2,000 and preferably from 1 to 1,000. Examples of suitable amino alcohols include amino alcohols selected from the group consisting of ethanol amine, isopropanol amine, 3-amino-1-propanol, 4-amino-1-butanol, 4-amino-2-butanol, 2-amino-1-butanol and 2-(2-aminoethoxy)ethanoI.
Examples of suitable diamines include d i~m i nes selected 7 ~
from the group consisting of ethylene diamine, 1,2-diaminopropane, 1,3-diaminopropane, 1,4-diaminobutane, 1,4-diaminocyclohexane and 1,S-diamino-3-oxapentane.
Examples of suitable diols include diols selected from the group consisting of 1,2-ethanediol (ethylene glycol), 1,2-propanediol (propylene glycol), 1,3-propanediol, 1,4-butanediol, 1,S-pentanediol, 1,3-cyclopentanediol, 1,6-hexanediol, 1,4-cyclohexanediol, 1,8-octanediol and combinations thereof. Examples of preferred polydiols include polydiols selected from the group consisting of polyethylene glycol (H[-O-CH2-CH2-]~OH) and pol~Lo~ylene glycol (H[-O-CH2-CH(CH3)-]~OH).
The polymer produced by reacting the aliphatic dioxacarboxylic acid with the amino alcohols discllcc~
above should provide a polymer generally having the formula:
t-O-C(O)-C(RI)(R2)-O-(R3)-O-C(R~)(R2)-C(O)-(N(RI2)-RI3)u~]l VIIA
wherein Rl, R2, R3, Rl2, Rl3 and U are as described above; and J is an integer in the range of from about 1 to about 10,000 and preferably is in the range of from about 10 to about 1,000 and most preferably in the range of from about SO to about 200.
The polymer produced by reacting the aliphatic dioxacarboxylic acid with the diamine discussed above should provide a polymer generally having the formula:
t-N(RI6)-C(O)-C(RI) (R2)-O-(R3)-O-C(RI) (R2)-c(o)-(N(Rl4)-Rl5)v-]J
VIIB
wherein Rl, R2, R3, Rl4, Rl5, Rl6 V and J are as described above.
Q ~ 9 .
The polymer produced by reacting the aliphatic dioxacarboxylic acid with a mixture of aminoalcohols, diols and diamines discussed above should provide a polymer generally having end groups that may be active amines or hydroxyl groups.
Suitable lactone monomers that may be used in the present invention generally have the formula:
~0-R~-C(0)~ VDI
These lactone monomers (or equivalent acids if any) may be polymerized to provide polymers of the following general structures:
Ht-O~R5~c(0)-3soH IX
(Ht ~O~Rg~C (O) ] p-O-) LG X
wherein ~ and ~ are independently selected from the group consisting of -C(~)(~)-, -(CH2)3-0-, -CH2-CH2-0-CH2-, -C~H-CH2-~ -(CH2)4-~ -(C~)p-O-c(O)- and -(CH2)K-C(O)-CH2-; R6 and ~ are i~p~nAently selected from the group consisting of l.yd~G~en and an alkyl containing from l to 8 carbon atoms;
~ is selected from the group consisting of hydrogen and methyl; F and K are integers in the range of from 2 to 6;
B is an integer in the range of from l to n such that the number average molecular weight of formula IX is less than about 200,000, preferably less than about lO0,000, more preferably less than about 40,000 and most preferably less than 20,000; P is an integer in the range of from l to m such that the number average molecular weight of formula X is less than about l,OOO,Ooo, preferably less than about ~ 2 ~ 7 ~
g 200,000, more preferably less than about 40,000 and most preferably less than 20,000; G represents the residue minus from l to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from l to about 200 hydroxyl groups; and L is an integer from about l to about 200. Preferably G will be the residue of a dihydroxy alcohol minus both hydroxyl groups. Suitable lactone-derived repeatinq units may be generated from the following monomers include but are not limited to lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, meso-lactide, ~-caprolactone, p-dioxanone, trimethylene carbonate, l,4-dioxepan-2-one, l,5-dioxepan-2-one and combinations thereof.
The polymer formed by reacting the above described amino alcohols, diamines, and diol (or polydiol) VI with the appropriate aliphatic oxadicarboxylic acid or aliphatic polyoxydicarboxylic acid V may also be copolymerized in a ~on~ry ring-opening polymerization with the lactone monomers XIII or in a con~P~c~tion copolymerization with the lactone oligomers IX or X, described above to form a polymer generally of the formula:
t(-C(O)-C(R~)(R2)-O-R3-O-C(RI)(R2)-C(O)-(Y-R4)~-X)s~
~(C(O)-Rs-o)s]w XII
or t(-C(O)-C(RI)(R2)-O-R3-O-C(Rl)(R2)-C(O)-(Y-~) A X) 5 -(~-O-~-c(o)]p-o-)LG~w XIII
30 wherein X and Y are selected from the group consisting of -O- and N(R), provided that X and Y cannot both be -O-;
and S is an integer in the range of from about l to about lO,000 and is preferably an integer in the range of from about l to about l,000 and W is an integer in the range of ErH-1120 ~ ~ ~ Q~ a 7 9 from about 1 to about 1,000. These polymers may be made in the form of random copolymers or block copolymers. To the compounds described above there may be added a coupling agent selected from the group consisting of trifunctional or tetrafunctional polyols, oxycarboxylic acids, and polybasic carboxylic acids (or acid anhydrides thereof). The addition of the coupling agents causes the br~hing of long chains, which can impart desirable properties in the molten state to the polyester prepolymer. Examples of suitable polyfunctional coupling agents include trimethylol propane, glycerin, pentaerythritol, malic acid, citric acid, tartaric acid, trimesic acid, propane tricarboxylic acid, cyclopentane tetracarboxylic anhydride, triethanol amine and combinations thereof.
The amount of coupling agent to be added before gelation O~lS is a function of the type of coupling agent used and the polymerization conditions of the polyoxaamide or 20 molec~ r weight of the prepolymer to which it is added.
Generally in the range of from about 0.1 to about 10 mole percent of a trifunctional or a tetrafunctional coupling agent may be added based on the moles of aliphatic polyoxaamide polymers present or anticipated from the synthesis.
The preparation of the aliphatic polyoxaamides (which also includes polyoxaesteramides) are preferably polymerizations performed under melt polycondensation conditions at elevated temperatures. At times it may be preferably to add a catalyst such as an organometallic compound. Preferred organometallic catalysts are tin-based catalysts e.g. stannous octoate. The catalyst will preferably be present in the mixture at a mole ratio ~ ~ ~ 9 ~ ~ 7 ~
of hydroxy groups, aliphatic polyoxydicarboxylic acid and optionally lactone monomer to catalyst will be in the range of from about 5,000 to about 80,000/1. The reaction is preferably performed at a temperature no less than about 120~C under reduced pressure. Higher polymerization temperatures may lead to further increases in the molecular weight of the copolymer, which may be desirable for numerous applications.
The exact reaction conditions chosen will depend on numerous factors, including the properties of the polymer desired, the viscosity of the reaction mixture, and the glass transition temperature and softening temperature of the polymer. The preferred reaction conditions of temperature, time and pressure can be readily determined by assessing these and other factors.
Generally, the reaction mixture will be maintained at about 220~C. The polymerization reaction can be allowed to proceed at this temperature until the desired mol~c~lAr weight and percent conversion is achieved for the copolymer, which will typically take about lS minutes to 24 hours. Increasing the reaction temperature generally decreases the reaction time needed to achieve a particular molecular weight, but may also increase the extent of side reactions. We have found that reaction at about 220-C to be generally suitable.
In another emho~ment, aliphatic polyoxaamide copolymers can be prepared by forming an aliphatic polyoxaamide prepolymer polymerized under melt polycondensation conditions, then adding at least one lactone monomer or lactone prepolymer. The mixture would then be subjected to the desired conditions of temperature and time to copolymerize the prepolymer with the lactone monomers. If ErH-1120 - -a lactone prepolymer is used, a polycondensation reaction can be used to increase the molecular weight.
The molecular weight of the prepolymer as well as its composition can be varied depending on the desired characteristic which the prepolymer is to impart to the copolymer. However, it is preferred that the aliphatic polyoxaamide prepolymers from which the copolymer is prepared have a molecular weight that provides an inherent viscosity between about 0.2 to about 2.0 deciliters per gram (dl/g) as measured in a 0.l g/dl solution of hexafluoroisopropanol at 25~C. Those skilled in the art will recognize that the aliphatic polyoxaamide prepolymers described herein can also be made from mix~u~es of more than one diol, amino alcohol, or dioxacarboxylic acid.
One of the beneficial properties of the aliphatic polyoxaamide made by the process of this invention is that the ester linkages are hydrolytically unstable, and therefore the polymer is bioabsorbable because it readily breaks down into small segments when exposed to moist bodily tissue. In this regard, while it is envisioned that co-reactants could be incorporated into the reaction mixture of the aliphatic dioxacarboxylic acid and the diol for the formation of the aliphatic polyoxaamide prepolymer, it is preferable that the reaction mixture does not contain a concentration of any co-reactant which would render the subsequently prepared polymer non~h~Qrbable. Preferably, the reaction mixture is substantially free of any such co-reactants if the resulting polymer is rendered nonabsorbable.
These aliphatic polyoxaamides of the present invention and those described in Serial No. 08/399,308, filed March 6, ErH-1120 1995 and assigned to Ethicon, now U.S. Patent No.
5,464,929 may be blended together with other homopolymers copolymers and graft copolymers to impart new properties to the material formed by the blend. The other polymers which the aliphatic polyoxaamides may be blended with include but are not limited to homopolymer and copolymer of lactone type polymers with the repeating units described by Formula VIII, polyesters (such as adipates) aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers (such as ethylene-vinyl acetate copolymers and ethylene ethyl acrylate copolymers), polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate). The copolymers (i.e. containing two or more repeating units) including random, block and segmented copolymers. Suitable lactone-derived repeating units may be generated from the following monomers include but are not limited to lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, meso-lactide, ~-caprolactone, p-dioxanone, trimethylene carbonate, l,4-dioxepan-2-one, l,5-dioxepan-2-one and combinations thereof. The blends may contain about l weight percent to about 99 weight percent of the aliphatic polyoxaamides.
For some applications it may be desirable to add additional ingredients such as stabilizers, antioxidants radiopacifiers, fillers or the like.
The aliphatic polyoxaamide and other polymers may be blended using conventional mixing processes known in the art. For example a blend can be prepared using a two-roll ErH-1120 ~ 2 ~ Q7 ~
mill, an internal mixer (such as a Brabender or Banbury mixer), an extruder (such as a twin screw extruder) or the like.
The polymer blends of this invention can be melt processed by numerous methods to prepare a vast array of useful devices. These polymer blends can be injection or compression molded to make implantable medical and surgical devices, especially wound closure devices. The preferred wound closure devices are surgical clips, staples and sutures.
Alternatively, the polymer blends can be extruded to prepare fibers. The filaments thus produced may be fabricated into sutures or ligatures, attached to surgical needles, packaged, and sterilized by known tec~n;ques.
The polymers of the present invention may be spun as multifilament yarn and woven or knitted to form sponges or gauze, (or non-woven sheets may be prepared) or used in conjunction with other molded compressive structures as prosthetic devices within the body of a human or animal where it is desirable that the structure have high tensile strength and desirable levels of compliance and/or ductility. Useful embodiments include tubes, including brAnc~e~ tubes, for artery, vein or intestinal repair, nerve splicing, tendon splicing, sheets for typing up and --u~o~ing damaged surface abrasions, particularly major abrasions, or areas where the skin and underlying tissues are damaged or surgically removed.
Additionally, the polymer blends can be molded to form films which, when sterilized, are useful ~s adhesion prevention barriers. Another alternative processing tech~i~ue for the polymer blends of this invention ErH-1120 7 ~
includes solvent casting, particularly for those applications where a drug delivery matrix is desired.
In more detail, the surgical and medical uses of the filaments, films, and molded articles of the present invention include, but are not necessarily limited to:
Knitted products, woven or non-woven, and molded products including:
a. burn dressings b. hernia patches c. medicated dressings d. fascial substitutes e. gauze, fabric, sheet, felt or sponge for liver hemostasis f. gauze bandages g. arterial graft or substitutes h. bandages for skin surfaces i. ~uL~e knot clip j. or~hop~ic pins, clamps, screws, and plates k. clips (e.g.,for vena cava) l. staples m. hooks, buttons, and snaps n. bone substitutes (e.g., mandible prosthesis) o. intrauterine devices (e.g.,spermicidal devices) p. draining or testing tubes or capillaries q. surgical instruments r. vA~ 1Ar implants or supports s. vertebral discs t. extracorporeal tubing for kidney and heart-lung machines u. artificial skin and others v. catheters (including, but not limi~e3 to, the catheters described in U.S. Patent No. 4,883,699 ErH-1120 -- O ~ ~9 Q7 ~
which is hereby incorporated by reference) w. scaffoldings and the like for tissue engineering applications.
In another embodiment, the polymer blends can be used to coat a surface of a surgical article to enhance the lubricity of the coated surface. The polymer blends may be applied as a coating using conventional techniques.
For example, the polymer blends may be solubilized in a dilute solution of a volatile organic solvent, e.g.
acetone, methanol, ethyl acetate or toluene, and then the article can be immersed in the solution to coat its surface. Once the surface is coated, the surgical article can be removed from the solution where it can be dried at room or elevated temperatures until the solvent and any residual reactants are removed.
For use in coating applications the polymer blends should exhibit an inherent viscosity, as measured in a 0.l gram per deciliter (g/dl) of hexafluoroisopropanol (HFIP), between about 0.05 to about 2.0 dl/g, preferably about 0.l0 to about 0.80 dl/g. If the inherent viscosity were less than about 0.05 dl/g, then the polymer blends may not have the integrity nereCs~ry for the preparation of films or coatings for the surfaces of various surgical and medical articles. On the other hand, although it is possible to use polymer blends with an inherent viscosity greater than about 2.0 dl/g, it may be exr~e~ingly difficult to do so.
Although it is contemplated that numerous surgical articles (including but not limited to endoscopic instruments) can be coated with the polymer blends of this invention to improve the surface properties of the article, the preferred surgical articles are surgical sutures and needles. The most preferred surgical article is a suture, most preferably attached to a needle.
Preferably, the suture is a synthetic absorbable suture.
These ~uLuLes are derived, for example, from homopolymers and copolymers of lactone monomers such as glycolide, lactide, ~-caprolactone, l,4-dioxanone, and trimethylene carbonate. The preferred suture is a braided multifilament suture composed of polyglycolide or poly(glycolide-co-lactide).
The amount of polymer blend to be applied on the surface of a braided suture can be readily determined empirically, and will depend on the particular copolymer and ~uLule 5 ~h9c~. Ideally, the amount of polymer blend applied to the surface of the suture may range from about 0.5 to about 30 percent of the weight of the coated ~uL~e, more preferably from about l.0 to about 20 weight percent, most preferably from l to about 5 weight percent. If the amount of coating on the suture were greater than about 30 weight percent, then it may increase the risk that the coating may flake off when the suture is pacsed through tissue.
Sutures coated with the polymer blends of this invention are desirable because they have a more slippery feel, thus making it easier for the surgeon to slide a knot down the ~uL~e to the site of surgical trauma. In addition, the ~uLu~e can be p~qe~ more easily through body tissue thus reducing tissue trauma. These advantages are exhibited in comparison to sutures which do not have their surfaces coated with the polymer blends of this invention.
In another embodiment of the present invention when the 7 ~
article is a surgical needle, the amount of coating applied to the surface of the article is an amount which creates a layer with a thickness ranging prefera~ly between about 2 to about 20 microns on the needle, more preferably about 4 to about 8 microns. If the amount of coating on the needle were such that the thickness of the coating layer was greater than about 20 microns, or if the thickness was less than about 2 microns, then the desired performance of the needle as it is passed through tissue may not be achieved.
In another embodiment of the present invention, the polymer blends can be used as a pharmaceutical carrier in a drug delivery matrix. To form this matrix the polymer blends would be mixed with a therapeutic agent to form the matrix. The variety of different therapeutic agents which can be used in conjunction with the polymer blends of the present invention is vast. In general, therapeutic agents which may be administered via the pharmaceutical compositions of the invention include, without limitation:
antiinfectives such as antibiotics and antiviral agents;
analgesics and analgesic combinations; anorexics;
antihelmintics; antiarthritics; antiasthmatic agents;
anticonvulsants; antidepressants; antidiuretic agents;
antidiarrheals; antihistamines; antiinflammatory agents;
antimigraine preparations; antinauseants; antineoplastics;
antiparkinsonism drugs; antipruritics; antipsychotics;
antipyretics, antispasmodics; anticholinergics;
sympathomimetics; xanthine derivatives; cardiovA~c~1Ar preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics;
antihypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including . CA 02199079 1997-03-04 7 ~
, decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics;
immunosuppressives; muscle relaxants; parasympatholytics;
psychostimulants; sedatives; and tranquilizers; and naturally derived or genetically engineered proteins, polysaccharides, glycoproteins, or lipoproteins.
The drug delivery matrix may be administered in any suitable dosage form such as oral, parenteral, a subcutaneously as an implant, vaginally or as a ~ ository. Matrix formulations containing the polymer blends may be formulated by mixing one or more therapeutic agents with the blends. The therapeutic agent, may be present as a liquid, a finely divided solid, or any other a~lo~}iate physical form. Typically, but optionally, the matrix will include one or more additives, e.g., nontoxic auxiliary substances such as diluents, carriers, excipients, stabilizers or the like. Other suitable additives may be formulated with the blends and pharmaceutically active agent or compound, however, if water is to be used it should be added immediately before administration.
The amount of therapeutic agent will be dependent upon the particular drug employed and medical condition being treated. Typically, the amount of drug represents about 0.001% to about 70%, more typically about 0.001% to about 50%, most typically about 0.001% to about 20% by weight of the matrix.
The quantity and type of polymer blends incorporated into the parenteral will vary depending on the release profile desired and the amount of drug employed. The product may contain blends of polymers of different molecular weights ErH-1120 . CA 02199079 1997-03-04 7 ~
to provide the desired release profile or consistency to a given formulation.
The polymer blends, upon contact with body fluids including blood or the like, undergoes gradual degradation (mainly through hydrolysis) with concomitant release of the dispersed drug for a sustained or extended period (as compared to the release from an isotonic saline solution).
This can result in prolonged delivery (over, say l to 2,000 hours, preferably 2 to 800 hours) of effective amounts (say, O.OOOl mg/kg/hour to lO mg/kg/hour) of the drug. This dosage form can be administered as is neceeC~ry depending on the subject being treated, the severity of the affliction, the judgment of the prescribing physician, and the like.
Individual formulations of drugs and polyoxaamide may be tested in appropriate in vitro and in vivo models to achieve the desired drug release profileQ. For example, a drug could be formulated with a polyoxaamide and orally administered to an animal. The drug release profile could then be monitored by appropriate means such as, by ~i nq blood samples at specific times and assaying the samples for drug concPntration. Following this or similar ~e~1 ~es, those skilled in the art will be able to formulate a variety of formulations.
The polymers, copolymers and blends of the present invention can be crosslinked to affect mech~nical properties. Crosslinking can be accomplished by the addition of crosslinking ~h~ncers and/or irradiation (such as gamma-irradiation). In particular, crosslinking can be used to ~o"L~ol the water swellablity of said invention.
ErH-1120 In a further embodiment of the present invention the polyoxaamide polymers and polymer blends of the present invention can be used in tissue engineering applications as supports for cells. Appropriate tissue scaffolding structures are known in the art such as the prosthetic articular cartilage described in U.S. Patent 5,306,311, the porous biodegradable scaffolding described in WO 94/25079, and the prevascularized implants described in WO 93/08850. Methods of seeding and/or culturing cells in tissue scaffoldings are also known in the art such as those methods disclosed in EPO 422 209 Bl, WO 88/03785, WO 90/12604 and WO 95/33821.
The Examples set forth below are for illustration purposes only, and are not intended to limit the scope of the claimed invention in any way. Numerous additional embodiments within the scope and spirit of the invention will become readily apparent to those skilled in the art.
ExamPle 1 Preparat$on of 3,6-Diox~octanedioic acid and its dimethylester HO~_~-~o,~~_~O~_'~'OH HN~ ~ ~ OH
Tr. b'.JlPn~ glycol 3,6-r~ ' acid H+
O
~0~~~oa~
D~es~rof3.~. I e~cil The diacid, 3,6-dioxaoctanedioic acid, was syn~hesiz~ by oxidation of triethylene glycol. The oxidation was carried out in a 500 milliliter, three-neck round bottom flask equipped with a thermometer, an additional funnel, a gas absorption tube and a magnetic spinbar. The reaction flask was lowered into an oil bath resting upon a magnetic stirrer. To the reaction flask was added 157.3 ml of a 60%
nitric acid solution; 37.0 g of triethylene glycol was added to the additional funnel. The contents of the flask were heated to 78-80 C. A test tube containing 0.5 g of glycol and one milliliter of concentrated nitric acid was warmed in a water bath until brown fumes started appearing. The contents were then added to the reaction flask. The mixture was stirred for a few minutes; the glycol was then carefully added. The rate of addition had to be monitored extremely carefully to keep the reaction 7 ~
under control. The addition rate was slow enough so that the temperature of the exothermic reaction mixture was maintained at 78-82 C. After the addition was completed (80 minutes), the temperature of the reaction mixture was maintained at 78-80 C for an additional hour. While continuing to maintain this temperature range, the ~Ycecc nitric acid and water was then distilled off under re~llse~
pressure (water suction). The syrupy residue was cooled;
some solids appeared. The reaction product had the IR and 10 NMR spectra expected for the dicarboxylic acid; the crude product was used as such for esterification.
The crude diacid could be purified to the extent neP~e~
for polymerization or alternately could be converted to the co~e~ponding diester, the diester purified and ~ubsequently hydrolyzed back to (purified) diacid. In yet another mode of purification, the diamine salts of the diacids are purified and then subsequently polymerized to form the polyoxaamides of the present invention.
Esterification of the crude 3,6-dioxaoctanedioic acid was accomplished as follows: To the reaction flask cont~i~in~
36 g of the crude diacid, was added 110 ml of methanol.
This was stirred for 3 days at room temperature after which 15 g of sodium bicarbonate was added and stirred overnight. The mixture was filtered to remove solids. To the liquor was added an additional 10 g of sodium bicarbonate; this mixture was stirred overnight. The mixture was again filtered; the liquor was fractionally distilled. NMR analysis of the esterified product showed a mixture of dimethyl triglycolate (78.4 mole%) and monomethyltriglycolate (21.6 mole%). No significant con~Pn~tion of diacid was observed.
Q 7 ~
ExamPle 2 Preparation of polyoxaesteramide from 3,6-dioxaoctanedioic acid and ethanolamine ~~o~ ~~D'OH + HOCH2CH2NH2 3,6-diox~oct~nedioic acid ~O - ~O~Jl~N~
Polyoxaesteramides A flame dried, me~n;cally stirred, 50-milliliter glass reactor suitable for polycondensation reaction, is charged 20 with the equivalent of 0.1 mole of purified 3,6-dioxaoctanedioic acid from Example 1 (17.81g), and 0.1 mole of ethanolamine (6.11g). This generally could be done by charging the reactor with exact stoichometric amounts of the diacid and the amino alcohol; alternately 25 a small eYcecc of ethylene glycol can be substituted for a portion of the amino alcohol. The polymerization can be ~on~ltcted without additional catalyst or alternately a small amount of catalyst (eg. 0.0606 ml of a solution of 0.33M stannous octoate in toluene) can be added. After purging the reactor and venting with nitrogen, the temperature is gradually raised over the course of 26 hours to 180 C. A temperature of 180-C is then maintained for another 20 hours; all during these heating periods under nitrogen at one atmosphere, the water formed is collected. The reaction flask is allowed to cool to room temperature; it is then slowly heated under reduced pressure (0.015-1.0 mm) over the course of about 32 hours to 160-C, during which time additional distillates can be collected. A temperature of 160-C i5 maintained for 4 hours after which a sample, a few grams in size, of the polymer formed is taken. The sample is found to have an inherent viscosity (I.V.) of approximately 0.2 dl/g, as determined in hexaflouroisopropanol (HFIP) at 25 C at a concentration of 0.1 g/dl. The polymerization is continued under reduced pressure while raising the temperature, in the course of about 16 hours, from 160-C to 180-C; a temperature of 180-C is maintained for an additional 8 hours, at which time a polymer sample is taken and found to have an I.V. of approximately 0.3 dl/g. The reaction is contin-lP~ under reduced pressure for another 8 hours at 180-C. The resulting polymer should have an inherent viscosity of approximately 0.4 dl/g, as determined in HFIP
at 25-C and at a concentration of 0.1 g/dl.
7 ~
Example 3 Preparation of polyoxa~mide with 3,6,9-trioxaundecanedioic 5acid and ethylene diamine HO ~ ,~_,O~_,_~ ~ OH + H2NCH2CH2NH2 O O
3,6,~Trioxaundecanedioic acid ~f ~O ~o~N~~N~n O O
Polyoxaamides A flame dried, mechanically stirred, 250-milliliter glass reactor, suitable for polycondensation reaction, is charged with the equivalent of 0.2 mole (44.44 g) of 3,6,9-trioxaundecanedioic acid, and 0.2 mole (12.02 g) of ethylene diamine; this can be conveniently done by charging the reactor with the stoichometric salt formed between the diacid and the diamine. Alternately a small excess of ethylene glycol can be substituted for a portion of the diamine. The polymerization can be conducted without additional catalyst or alternately a small amount of catalyst (eg. 0.0606 ml of a solution of 0.33M stannous octoate in toluene or 10 milligrams of dibutyltin oxide) can be added.
After purging the reactor and venting with nitrogen, the contents of the reaction flask are gradually heated under nitrogen at one atmosphere, in the course of about 32 ErH-1120 . CA 02199079 1997-03-04 7 ~
hours, to 180 C, during which time the water formed is collected. The reaction mass is allowed to cool to room temperature. The reaction mass is then heated under reduced pressure (0.015-1.0 mm), gradually increasing the temperature to 180 C in about 40 hours; during this time additional distillates is collected. The polymerization is continued under reduced pressure while maintaining 180-C
for an additional 16 hours. The resulting polymer should have an inherent viscosity of approximately 0.5 dl/g as determined in HFIP at 25 C and at a concentration of 0.1 g/dl.
~xamDle 4 Proparation of polyoxaamide with polyglycol diacid and Jeffamine o HO~O~~Om~OH + H2N~Q~n~NH2 Polyglycol dlscld [m=1 1l J~mln~ [n=1 1l O
~~~m ~N~0~3~o~N}~
O H
P~ I s A flame dried, mechAnically stirred, 500-milliliter glass reactor (suitable for polycondensation reaction) i8 charged with the equivalent of 0.2 mole (123.8 g) of polyglycol diacid (molecular weight about 619), and 0.2 mole (117.7g) of Jeffamine (amine terminated polyethylene oxide). This generally could be done by charging the reactor with stoichometric amounts of the diac~d and the diamine or by charging the corresponding preformed salt of ErH-l120 the diacid and diamine. As an alternate process, a small excess of ethylene glycol can be substituted for a portion of the diamine. The polymerization can be conducted without additional catalyst or alternately a small amount of catalyst. After purging the reactor and venting with nitrogen, the contents of the reaction flask is heated under nitrogen at one atmosphere, gradually increasing the temperature to 200 C in about 32 hours; during this time the water formed is collected. The reaction flask is heated gradually under reduced pressure (O.OlS-1.0 mm) from room temperature to 140-C in about 24 hours, during which time additional distillates are collected. A polymer sample of about ten grams is taken at this stage, and found to have an I.V. of approximately 0.1 dl/g in HFIP at 25-C, 0.1 g/dl. The polymerization is continued under reduced pressure while heating from 140-C to 180-C in about 8 hours, and then maintained at 180-C for an additional 8 hours. The reaction temperature is then increased to l90 C and maintained there under re~l~c~
pressure for an additional 8 hours. The resulting polymer should have an inherent viscosity of approximately 0.6 dl/g as determined in HFIP at 25 C and at a concentration of 0.1 g/dl.
ErH-1120
Claims (52)
1. An aliphatic polyoxaamides comprising a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-]
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-] T, II
[-O-R5-C(O)-] B, III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)B- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-)-, -CH2-CH2-O-CH2-, -CR8H-CH2-, - (CH2) 4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-]
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-] T, II
[-O-R5-C(O)-] B, III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)B- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-)-, -CH2-CH2-O-CH2-, -CR8H-CH2-, - (CH2) 4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200.
2. The aliphatic polyoxaamides of claim 1 wherein the number average molecular weight of formula III is less than 100,000.
3. The aliphatic polyoxaamides of claim 1 wherein the polymer has the formula:
[(-C(O)-C(R1) (R2)-O-R3-O-C(R1) (R2)-C(O)-(Y-R17)T-X)S
(C(O)-R5-O) B]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1) (R2)-O-R3-O-C(R1) (R2)-C(O)-(Y-R17)T-X)S
(C(O)-R5-O) B]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
4. The aliphatic polyoxaamides of claim 1 wherein the polymer has the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)s ([-O-R9-C(O)]P-O-)LG]w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)s ([-O-R9-C(O)]P-O-)LG]w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
5. A device made from an aliphatic polyoxaamides comprising a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-]
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, II
[-O-R5-(O)-]B, III
[-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-, R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein c is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-]
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, II
[-O-R5-(O)-]B, III
[-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-, R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein c is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200.
6. The device of claim 5 wherein the device is an absorbable surgical device.
7. The absorbable surgical device of claim 6 wherein the absorbable surgical device is selected from the group consisting of burn dressings, hernia patches, medicated dressings, fascial substitutes, gauze, fabrics, sheets, felts, sponges, gauze bandages, arterial graft, bandages for skin surfaces, suture knot clip, pins, clamps, screws, plates, clips, staples, hooks, buttons, snaps, bone substitutes, intrauterine devices, tubes, surgical instruments, vascurlar implants, vascular supports, vertebral discs, and artificial skin.
8. The absorbable surgical device of claim 6 wherein the device is a filament.
9. The filament of claim 8 wherein the filament is attached to a needle.
10. A device coated with an absorbable coating comprising an aliphatic polyoxaamides having a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-]
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, II
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, - (CH2)3-O- , -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200; wherein the inherent viscosity of the polyoxaamide is in the range of from about 0.05 to about 2.0 deciliters per gram (dl/g) as measured in a 0.1 g/dl solution of hexafluoroisopropanol (HFIP) at 25°C.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-]
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, II
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, - (CH2)3-O- , -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200; wherein the inherent viscosity of the polyoxaamide is in the range of from about 0.05 to about 2.0 deciliters per gram (dl/g) as measured in a 0.1 g/dl solution of hexafluoroisopropanol (HFIP) at 25°C.
11. The device of claim 10 wherein the device is a suture.
12. The device of claim 11 wherein the suture is attached to a needle.
13. A drug delivery matrix comprising a drug and an aliphatic polyoxaamide having a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, II
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit contaiting from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, - (CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, II
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit contaiting from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, - (CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200.
14. The device of claim 5 wherein the number average molecular weight of formula XI is less than 200,000.
15. The device of claim 5 wherein the aliphatic polyoxaamides have the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)s (C(O)-R5-) B]w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)s (C(O)-R5-) B]w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
16. The device of claim 5 wherein the aliphatic polyoxaamides have [(-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-(Y-R17)T-X)s ([-O-R9-C(O)]P-O-)LG]w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
17. The device coated with an absorbable coating of claim wherein the aliphatic polyoxaamides have the formula:
[-O-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-(O-R17)T-]N
wherein N is an integer in the range of from about 1 to about 10,000.
[-O-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-(O-R17)T-]N
wherein N is an integer in the range of from about 1 to about 10,000.
18. The device coated with an absorbable coating of claim wherein the aliphatic polyoxaamides have the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-x)S
(C(O)-R5-O)B]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-x)S
(C(O)-R5-O)B]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
19. The device coated with an absorbable coating of claim wherein the aliphatic polyoxaamides have the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(y-R17)T-X)S
([-O-R9-C(O)]P-O-)LG]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(y-R17)T-X)S
([-O-R9-C(O)]P-O-)LG]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
20. The drug delivery matrix of claim 13 wherein the aliphatic polyoxaamide has the formula:
[-O-C(O)-C(RI) (R2)-O--(R3)-O-C(RI) (R2)-C(O)-(O-RI7)T-]N
wherein N is an integer in the range of from about 1 to about 10,000.
[-O-C(O)-C(RI) (R2)-O--(R3)-O-C(RI) (R2)-C(O)-(O-RI7)T-]N
wherein N is an integer in the range of from about 1 to about 10,000.
21. The drug delivery matrix of claim 13 wherein the number average weight of formula XI is less than 200,000.
22. The drug delivery matrix of claim 13 wherein the aliphatic polyoxaamide has the formula:
t(-C(0)-C(RI)(R2)-0-R3-0-C(R~)(R2)-C(0)-(Y-~I7)T-x)s ( t--O--~4--C (°) ] P--O--) LG] w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
t(-C(0)-C(RI)(R2)-0-R3-0-C(R~)(R2)-C(0)-(Y-~I7)T-x)s ( t--O--~4--C (°) ] P--O--) LG] w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
23. The aliphatic polyoxaamide of claim 1 wherein the polyoxaamide contains as a second repeat unit a lactone derived repeating unit derived from lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, meso-lactide, ~-caprolactone, p-dioxanone, trimethylene carbonate, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and combinations thereof.
24. The device of claim 5 wherein the aliphatic polyoxaamide contains as a _~con~ repeat unit a lactone derived repeating unit derived from lactone monomers selected from the group consisting of glycolide, d-lactide, 1-lactide, meso-lactide, .epsilon.-caprolactone, p-dioxanone, trimethylene carbonate, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and combinations thereof.
25. The device coated with an absorbable coating of claim 10 wherein the aliphatic polyoxaamide in the coating contains as a second repeat unit a lactone derived repeating unit derived from lactone monomers selected from the group consisting of glycolide, d-lactide, 1-lactide, meso-lactide, .epsilon.-caprolactone, p-dioxanone, trimethylene carbonate, 1,4-dioxepan-2-one, 1, 5-dioxepan-2-one and combinations thereof.
26. The drug delivery matrix of claim 13 wherein the aliphatic polyoxaamide in the matrix contains as a second repeat unit a lactone derived repeating unit derived from lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, mesolactide, .epsilon.-caprolactone, p-dioxanone, trimethylene carbonate, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and combinations thereof.
27. A polymer blend comprising an aliphatic polyoxaamide composed of a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, I
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]p-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2) K-C (O) -CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200;
and a second polymer selected from the group consisting of homopolymer and copolymer of lactone type polymers with the repeating units described by formulas III and XI, aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate) and combinations thereof.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, I
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]p-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2) K-C (O) -CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200;
and a second polymer selected from the group consisting of homopolymer and copolymer of lactone type polymers with the repeating units described by formulas III and XI, aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate) and combinations thereof.
28. The polymer blend of claim 27 wherein the number average molecular weight of formula III is less than 100, 000.
29. The polymer blend of claim 27 wherein the polymer has the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
(C(O)-RS-O)B]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
(C(O)-RS-O)B]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
30. The polymer blend of claim 27 wherein the aliphatic polyoxaamides has the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
([-O-R9-C(O)]p-O-)LG]w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
([-O-R9-C(O)]p-O-)LG]w wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
31. A device made from a polymer blend comprising an aliphatic polyoxaamides composed of a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, I
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200;
and a second polymer selected from the group consisting of homopolymer and copolymer of lactone type polymers with the repeating units described by formulas III and XI, aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate) and combinations thereof.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, I
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]P-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200;
and a second polymer selected from the group consisting of homopolymer and copolymer of lactone type polymers with the repeating units described by formulas III and XI, aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate) and combinations thereof.
32. The device of claim 31 wherein the device is an absorbable surgical device.
33. The absorbable surgical device of claim 32 wherein the absorbable surgical device is selected from the group consisting of burn dressings, hernia patches, medicated dressings, fascial substitutes, gauze, fabrics, sheets, felts, sponges, gauze bandages, arterial graft, bandages for skin surfaces, suture knot clip, pins, clamps, screws, plates, clips, staples, hooks, buttons, snaps, bone substitutes, intrauterine devices, tubes, surgical instruments, vascular implants, vascular supports, vertebral discs, and artificial skin.
34. The absorbable surgical device of claim 32 wherein the device is a filament.
35. The filament of claim 34 wherein the filament is attached to a needle.
36. A device coated with a polymer blend comprising a blend of an aliphatic polyoxaamides having a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, I
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]p-o-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an aLkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)P-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200;
and a recond polymer selected from the group consisting of homopolymer and copolymer of lactone type polymers with the repeating units described by formulas III and XI, aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate) and combinations thereof wherein the inherent viscosity of the blend is in the range of from about 0.05 to about 2.0 deciliters per gram (dl/g) as measured in a 0.1 g/dl solution of hexafluoroisopropanol (HFIP) at 25°C.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-]T, I
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]p-o-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an aLkylene unit and an oxyalkylene group of the following formula:
-[(CH2)C-O-]D-(CH2)E- IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from 1 to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)P-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G
represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200;
and a recond polymer selected from the group consisting of homopolymer and copolymer of lactone type polymers with the repeating units described by formulas III and XI, aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate) and combinations thereof wherein the inherent viscosity of the blend is in the range of from about 0.05 to about 2.0 deciliters per gram (dl/g) as measured in a 0.1 g/dl solution of hexafluoroisopropanol (HFIP) at 25°C.
37. The device of claim 36 wherein the device is a suture.
38. The device of claim 37 wherein the suture is attached to a needle.
39. A drug delivery matrix comprising a drug and a polymer blend of an aliphatic polyoxaamide having a first divalent repeating unit of formula I:
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-] T, I
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]p-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)c-O-]D-(CH2)E - IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from l to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200; and a second polymer selected from the group consisting of homopolymer and copolymer of lactone type polymers with the repeating units described by formulas III and XI, aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate) and combinations thereof.
[X-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-] I
and a second repeating unit selected from the group of formulas consisting of:
[-Y-R17-] T, I
[-O-R5-C(O)-]B, III
([-O-R9-C(O)]p-O-)LG XI
and combinations thereof, wherein X and Y are selected from the group consisting of -O- and -N(R)-, provided that X and Y cannot both be -O-; R, R1 and R2 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R3 is selected from the group consisting of an alkylene unit and an oxyalkylene group of the following formula:
-[(CH2)c-O-]D-(CH2)E - IV
wherein C is an integer in the range of from 2 to about 5, D is an integer in the range of from 0 to about 2,000, and E is an integer in the range of from about 2 to about 5, except when D is zero, in which case E will be an integer in the range of from 2 to 12; R17 is an alkylene unit containing from 2 to 8 carbon atoms which may have substituted therein an internal ether oxygen, an internal -N(R18)- or an internal -C(O)-N(R21)-; T is an integer in the range of from l to 2,000; R18 and R21 are independently selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms; R5 and R9 are selected from the group consisting of -C(R6)(R7)-, -(CH2)3-O-, -CH2-CH2-O-CH2-, -CR8H-CH2-, -(CH2)4-, -(CH2)F-O-C(O)- and -(CH2)K-C(O)-CH2-; R6 and R7 are independently selected from the group consisting of hydrogen and an alkyl containing from 1 to 8 carbon atoms; R8 is selected from the group consisting of hydrogen and methyl; F and K are independently selected integer in the range of from 2 to 6; B is an integer in the range of from 1 to n such that the number average number average molecular weight of formula III is less than about 200,000; P is an integer in the range of from 1 to m such that the number average molecular weight of formula XI is less than about 1,000,000; G represents the residue minus from 1 to L hydrogen atoms from the hydroxyl groups of an alcohol previously containing from 1 to about 200 hydroxyl groups; and L is an integer from about 1 to about 200; and a second polymer selected from the group consisting of homopolymer and copolymer of lactone type polymers with the repeating units described by formulas III and XI, aliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, poly(hydroxy ethyl acrylate), poly(hydroxyethyl methacrylate) and combinations thereof.
40. The device of claim 31 wherein the number average molecular weight of formula XI is less than 200,000.
41. The device of claim 31 wherein the aliphatic polyoxaamides have the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
(C(O)-R5-O) B] W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
(C(O)-R5-O) B] W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
42. The device of claim 31 wherein the aliphatic polyoxaamides have [(-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
([-O-R9-C(O)]P-O-)LG]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
([-O-R9-C(O)]P-O-)LG]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
43. The device coated with the polymer blend of claim 36 wherein the aliphatic polyoxaamides have the formula:
[-O-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-(O-R17))T-]N
wherein N is an integer in the range of from about 1 to about 10,000.
[-O-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-(O-R17))T-]N
wherein N is an integer in the range of from about 1 to about 10,000.
44. The device coated with the polymer blend of claim 36 wherein the aliphatic polyoxaamides have the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
(C(O)-R5-O)B]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
(C(O)-R5-O)B]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
45. The device coated with the polymer blend of claim 36 wherein the aliphatic polyoxaamides have the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
([-O-R9-C(O)]P-O-)LG]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
([-O-R9-C(O)]P-O-)LG]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
46. The drug delivery matrix of claim 39 wherein the aliphatic polyoxaamide has the formula:
[-O-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-(O-R17))T-]N
wherein N is an integer in the range of from about 1 to about 10,000.
[-O-C(O)-C(R1)(R2)-O-(R3)-O-C(R1)(R2)-C(O)-(O-R17))T-]N
wherein N is an integer in the range of from about 1 to about 10,000.
47. The drug delivery matrix of claim 39 wherein the number average weight of formula XI is less than 200,000.
48. The drug delivery matrix of claim 39 wherein the aliphatic polyoxaamide has the formula:
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
([-O-R9-C(O)]P-O-)LG]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
[(-C(O)-C(R1)(R2)-O-R3-O-C(R1)(R2)-C(O)-(Y-R17)T-X)S
([-O-R9-C(O)]P-O-)LG]W
wherein S is an integer in the range of from about 1 to about 10,000 and W is an integer in the range of from about 1 to about 1,000.
49. The aliphatic polyoxaamide of claim 27 wherein the polyoxaamide contains as a second repeat unit a lactone derived repeating unit derived from lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, meso-lactide, .epsilon.-caprolactone, p-dioxanone, trimethylene carbonate, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and combinations thereof.
50. The device of claim 31 wherein the aliphatic polyoxaamide contains as a second repeat unit a lactone derived repeating unit derived from lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, meso-lactide, .epsilon.-caprolactone, p-dioxanone, trimethylene carbonate, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and combinations thereof.
51. The device coated with the polymer blend of claim 36 wherein the aliphatic polyoxaamide in the coating contains as a second repeat unit a lactone derived repeating unit derived from lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, meso-lactide, .epsilon.-caprolactone, p-dioxanone, trimethylene carbonate, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and combinations thereof.
52. The drug delivery matrix of claim 39 wherein the aliphatic polyoxaamide in the matrix contains as a second repeat unit a lactone derived repeating unit derived from lactone monomers selected from the group consisting of glycolide, d-lactide, l-lactide, mesolactide, .epsilon.-caprolactone, p-dioxanone, trimethylene carbonate, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and combinations thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/611,532 US5597579A (en) | 1995-03-06 | 1996-03-05 | Blends of absorbable polyoxaamides |
US08/611,532 | 1996-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2199079A1 true CA2199079A1 (en) | 1997-09-05 |
Family
ID=24449404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002199079A Abandoned CA2199079A1 (en) | 1996-03-05 | 1997-03-04 | Blends of absorbable polyoxaamides |
Country Status (10)
Country | Link |
---|---|
US (2) | US5597579A (en) |
EP (1) | EP0794211B1 (en) |
JP (1) | JPH107793A (en) |
CN (1) | CN1167126A (en) |
AU (1) | AU1507597A (en) |
BR (1) | BR9701197A (en) |
CA (1) | CA2199079A1 (en) |
DE (1) | DE69734905T2 (en) |
MX (1) | MX9701690A (en) |
ZA (1) | ZA971868B (en) |
Families Citing this family (173)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962023A (en) * | 1995-03-06 | 1999-10-05 | Ethicon, Inc. | Hydrogels containing absorbable polyoxaamides |
US5859150A (en) * | 1995-03-06 | 1999-01-12 | Ethicon, Inc. | Prepolymers of absorbable polyoxaesters |
US6403655B1 (en) | 1995-03-06 | 2002-06-11 | Ethicon, Inc. | Method of preventing adhesions with absorbable polyoxaesters |
US6100346A (en) * | 1995-03-06 | 2000-08-08 | Ethicon, Inc. | Copolymers of polyoxaamides |
US6147168A (en) | 1995-03-06 | 2000-11-14 | Ethicon, Inc. | Copolymers of absorbable polyoxaesters |
US5844017A (en) * | 1995-03-06 | 1998-12-01 | Ethicon, Inc. | Prepolymers of absorbable polyoxaesters containing amines and/or amido groups |
US5597579A (en) * | 1995-03-06 | 1997-01-28 | Ethicon, Inc. | Blends of absorbable polyoxaamides |
US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US5906617A (en) * | 1997-08-15 | 1999-05-25 | Meislin; Robert J. | Surgical repair with hook-and-loop fastener |
US6074660A (en) * | 1998-04-20 | 2000-06-13 | Ethicon, Inc. | Absorbable polyoxaesters containing amines and/ or amido groups |
US20020095157A1 (en) * | 1999-07-23 | 2002-07-18 | Bowman Steven M. | Graft fixation device combination |
US6179840B1 (en) | 1999-07-23 | 2001-01-30 | Ethicon, Inc. | Graft fixation device and method |
CA2365376C (en) * | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US6599323B2 (en) | 2000-12-21 | 2003-07-29 | Ethicon, Inc. | Reinforced tissue implants and methods of manufacture and use |
US6575986B2 (en) | 2001-02-26 | 2003-06-10 | Ethicon, Inc. | Scaffold fixation device for use in articular cartilage repair |
US6743232B2 (en) | 2001-02-26 | 2004-06-01 | David W. Overaker | Tissue scaffold anchor for cartilage repair |
US6656488B2 (en) * | 2001-04-11 | 2003-12-02 | Ethicon Endo-Surgery, Inc. | Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering |
BR0209198A (en) | 2001-04-26 | 2004-06-08 | Control Delivery Sys Inc | Synthesis methods of phenol-containing compounds |
EP1387670B1 (en) | 2001-05-11 | 2008-10-15 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Immune modulation device for use in animals |
US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
US20030003127A1 (en) | 2001-06-27 | 2003-01-02 | Ethicon, Inc. | Porous ceramic/porous polymer layered scaffolds for the repair and regeneration of tissue |
US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
US7819918B2 (en) * | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
JP2005515802A (en) * | 2001-07-16 | 2005-06-02 | デピュイ・プロダクツ・インコーポレイテッド | Hybrid / Synthetic Porous Extracellular Matrix Support Skeleton |
US7201917B2 (en) * | 2001-07-16 | 2007-04-10 | Depuy Products, Inc. | Porous delivery scaffold and method |
EP1416888A4 (en) * | 2001-07-16 | 2007-04-25 | Depuy Products Inc | Meniscus regeneration device and method |
US20030033021A1 (en) * | 2001-07-16 | 2003-02-13 | Plouhar Pamela Lynn | Cartilage repair and regeneration scaffold and method |
US8025896B2 (en) * | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
US20050027307A1 (en) * | 2001-07-16 | 2005-02-03 | Schwartz Herbert Eugene | Unitary surgical device and method |
US20030032961A1 (en) * | 2001-07-16 | 2003-02-13 | Pelo Mark Joseph | Devices from naturally occurring biologically derived materials |
US6916321B2 (en) * | 2001-09-28 | 2005-07-12 | Ethicon, Inc. | Self-tapping resorbable two-piece bone screw |
US6773436B2 (en) * | 2001-09-28 | 2004-08-10 | Depuy Mitek, Inc. | Absorbable bone anchor |
US6808518B2 (en) * | 2001-09-28 | 2004-10-26 | Ethicon, Inc. | Methods and devices for treating diseased blood vessels |
IL161733A0 (en) | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
US6921402B2 (en) * | 2001-12-27 | 2005-07-26 | Ethicon, Inc. | Polymer-based orthopedic screw and driver system with increased insertion torque tolerance and associated method for making and using same |
US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
US7824701B2 (en) * | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
US7491234B2 (en) | 2002-12-03 | 2009-02-17 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agents |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US8197837B2 (en) | 2003-03-07 | 2012-06-12 | Depuy Mitek, Inc. | Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof |
US8133257B2 (en) | 2003-06-27 | 2012-03-13 | Depuy Mitek, Inc. | Bioabsorbable suture anchor system for use in small joints |
US8226715B2 (en) * | 2003-06-30 | 2012-07-24 | Depuy Mitek, Inc. | Scaffold for connective tissue repair |
US10583220B2 (en) | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
US8257963B2 (en) * | 2007-06-01 | 2012-09-04 | Depuy Mitek, Inc. | Chondrocyte container and method of use |
US7897384B2 (en) * | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US7927599B2 (en) | 2003-09-08 | 2011-04-19 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US7244441B2 (en) * | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
US7316822B2 (en) | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
US7901461B2 (en) * | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
US20050149030A1 (en) * | 2003-12-19 | 2005-07-07 | Depuy Spine, Inc. | Facet joint fixation system |
US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
WO2005105172A1 (en) | 2004-04-20 | 2005-11-10 | Genzyme Corporation | Surgical mesh-like implant |
US8221780B2 (en) * | 2004-04-20 | 2012-07-17 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US8137686B2 (en) | 2004-04-20 | 2012-03-20 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US20050249772A1 (en) * | 2004-05-04 | 2005-11-10 | Prasanna Malaviya | Hybrid biologic-synthetic bioabsorbable scaffolds |
US7569233B2 (en) | 2004-05-04 | 2009-08-04 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
WO2006024038A2 (en) * | 2004-08-27 | 2006-03-02 | Codman & Shurtleff | Light-based implant for treating alzheimer’s disease |
US7354627B2 (en) * | 2004-12-22 | 2008-04-08 | Depuy Products, Inc. | Method for organizing the assembly of collagen fibers and compositions formed therefrom |
US20060142773A1 (en) | 2004-12-29 | 2006-06-29 | Depuy Mitek, Inc. | Abrasive cutting system and method |
US8007775B2 (en) | 2004-12-30 | 2011-08-30 | Advanced Cardiovascular Systems, Inc. | Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
WO2006089207A2 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
USRE47266E1 (en) | 2005-03-14 | 2019-03-05 | DePuy Synthes Products, Inc. | Light-based implants for treating Alzheimer's disease |
US7288108B2 (en) * | 2005-03-14 | 2007-10-30 | Codman & Shurtleff, Inc. | Red light implant for treating Parkinson's disease |
US7959938B2 (en) | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
US7862552B2 (en) * | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
US8092528B2 (en) | 2005-05-27 | 2012-01-10 | Depuy Spine, Inc. | Intervertebral ligament having a helical bone fastener |
US20060287676A1 (en) * | 2005-06-15 | 2006-12-21 | Rita Prajapati | Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use |
US20060286289A1 (en) * | 2005-06-15 | 2006-12-21 | Rita Prajapati | Method of intraoperative coating therapeutic agents onto sutures |
US20060287675A1 (en) * | 2005-06-15 | 2006-12-21 | Prajapati Rita T | Method of intra-operative coating therapeutic agents onto sutures composite sutures and methods of use |
US7351253B2 (en) * | 2005-06-16 | 2008-04-01 | Codman & Shurtleff, Inc. | Intranasal red light probe for treating Alzheimer's disease |
US7595062B2 (en) | 2005-07-28 | 2009-09-29 | Depuy Products, Inc. | Joint resurfacing orthopaedic implant and associated method |
US8167920B2 (en) * | 2005-10-31 | 2012-05-01 | Codman & Shurtleff, Inc. | Intranasal delivery of compounds that reduce intrancranial pressure |
US20070149916A1 (en) * | 2005-12-22 | 2007-06-28 | Alza Corporation | Dry matrices as drug reservoirs in electrotransport applications |
JP5143131B2 (en) | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | Two-piece internal channel flow modulator for osmotic delivery system |
US8709094B2 (en) * | 2006-06-26 | 2014-04-29 | DePuy Synthes Products, LLC | Anti-adhesion sheet |
US20080014152A1 (en) * | 2006-07-13 | 2008-01-17 | Di Mauro Thomas M | Intranasal delivery of clenbuterol across the cribriform plate and into the brain |
PL2359808T3 (en) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotic delivery systems and piston assemblies |
US20080081323A1 (en) * | 2006-09-29 | 2008-04-03 | Daniel Keeley | Regenerative Medicine Devices and Melt-Blown Methods of Manufacture |
US8114159B2 (en) | 2006-11-20 | 2012-02-14 | Depuy Spine, Inc. | Anterior spinal vessel protector |
WO2008070863A2 (en) | 2006-12-07 | 2008-06-12 | Interventional Spine, Inc. | Intervertebral implant |
US7871440B2 (en) * | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
US9039768B2 (en) | 2006-12-22 | 2015-05-26 | Medos International Sarl | Composite vertebral spacers and instrument |
EP1978051B1 (en) * | 2007-04-03 | 2012-02-22 | Rohm and Haas Electronic Materials, L.L.C. | Metal plating compositions and methods |
US8383865B2 (en) * | 2007-04-17 | 2013-02-26 | Codman & Shurtleff, Inc. | Curcumin derivatives |
WO2008131059A2 (en) | 2007-04-17 | 2008-10-30 | Codman & Shurtleff, Inc. | Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease |
MX2009011123A (en) | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Suspension formulations of insulinotropic peptides and uses thereof. |
US20080268016A1 (en) * | 2007-04-24 | 2008-10-30 | Fang Carrie H | Engineered Renal Tissue |
CN101072380B (en) * | 2007-06-08 | 2010-12-08 | 华为技术有限公司 | Content delivery method and system, network device, mobile data service management platform |
US8900307B2 (en) | 2007-06-26 | 2014-12-02 | DePuy Synthes Products, LLC | Highly lordosed fusion cage |
CA3115223A1 (en) | 2007-07-10 | 2011-01-13 | Implantica Patent Ltd. | Hip joint device and method |
EP2183280B1 (en) | 2007-08-01 | 2011-10-26 | Ethicon, Inc. | Collagen-related peptides and uses thereof |
US8062655B2 (en) * | 2007-08-31 | 2011-11-22 | Phillips Plastics Corporation | Composite scaffold structure |
US9247973B2 (en) | 2007-09-28 | 2016-02-02 | DePuy Synthes Products, Inc. | Anti-microbial implant |
JP5441922B2 (en) | 2008-01-17 | 2014-03-12 | ジンテス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Inflatable intervertebral implant and related manufacturing method |
US7745670B2 (en) * | 2008-06-27 | 2010-06-29 | Codman & Shurtleff, Inc. | Curcumin-Resveratrol hybrid molecule |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
US9320914B2 (en) | 2008-03-03 | 2016-04-26 | DePuy Synthes Products, Inc. | Endoscopic delivery of red/NIR light to the subventricular zone |
US20090248092A1 (en) | 2008-03-26 | 2009-10-01 | Jonathan Bellas | Posterior Intervertebral Disc Inserter and Expansion Techniques |
EP2262449B1 (en) | 2008-04-05 | 2020-03-11 | Synthes GmbH | Expandable intervertebral implant |
US7985776B2 (en) | 2008-06-27 | 2011-07-26 | Codman & Shurtleff, Inc. | Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease |
US20100021527A1 (en) * | 2008-07-25 | 2010-01-28 | Chunlin Yang | Collagen-related peptides and uses thereof and hemostatic foam substrates |
WO2010042049A1 (en) | 2008-10-10 | 2010-04-15 | Milux Holding S.A. | Composition, method and device for stabilizing implanted hydraulic devices |
US7723515B1 (en) * | 2009-01-26 | 2010-05-25 | Codman & Shurtleff, Inc. | Methylene blue—curcumin analog for the treatment of alzheimer's disease |
US20100286585A1 (en) * | 2009-01-26 | 2010-11-11 | Codman & Shurtleff, Inc. | Shunt Delivery of Curcumin |
US20100198316A1 (en) * | 2009-02-04 | 2010-08-05 | Richard Toselli | Intracranial Red Light Treatment Device For Chronic Pain |
US9526620B2 (en) | 2009-03-30 | 2016-12-27 | DePuy Synthes Products, Inc. | Zero profile spinal fusion cage |
US8403988B2 (en) * | 2009-09-11 | 2013-03-26 | Depuy Spine, Inc. | Minimally invasive intervertebral staple distraction devices |
US9615933B2 (en) * | 2009-09-15 | 2017-04-11 | DePuy Synthes Products, Inc. | Expandable ring intervertebral fusion device |
NZ598686A (en) | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
US9028553B2 (en) | 2009-11-05 | 2015-05-12 | DePuy Synthes Products, Inc. | Self-pivoting spinal implant and associated instrumentation |
EP2501431B1 (en) | 2009-11-19 | 2020-01-08 | Wellinq Medical B.V. | Narrow profile composition-releasing expandable medical balloon catheter |
CN102085394B (en) * | 2009-12-04 | 2013-07-17 | 远东新世纪股份有限公司 | Anti-platelet adhesion material |
US9393129B2 (en) | 2009-12-10 | 2016-07-19 | DePuy Synthes Products, Inc. | Bellows-like expandable interbody fusion cage |
US8979860B2 (en) | 2010-06-24 | 2015-03-17 | DePuy Synthes Products. LLC | Enhanced cage insertion device |
US8845733B2 (en) | 2010-06-24 | 2014-09-30 | DePuy Synthes Products, LLC | Lateral spondylolisthesis reduction cage |
TW201215379A (en) | 2010-06-29 | 2012-04-16 | Synthes Gmbh | Distractible intervertebral implant |
US8679159B2 (en) | 2010-08-30 | 2014-03-25 | Depuy Mitek, Llc | Anchor driver with suture clutch |
US8469998B2 (en) | 2010-08-30 | 2013-06-25 | Depuy Mitek, Llc | Knotless suture anchor |
US20120053627A1 (en) | 2010-08-30 | 2012-03-01 | DePuy Mikek, Inc. | Suture anchor and threader |
US8435264B2 (en) | 2010-08-30 | 2013-05-07 | Depuy Mitek, Llc | Knotless suture anchor and driver |
US8460340B2 (en) | 2010-08-30 | 2013-06-11 | Depuy Mitek, Llc | Knotless suture anchor |
US20120078372A1 (en) | 2010-09-23 | 2012-03-29 | Thomas Gamache | Novel implant inserter having a laterally-extending dovetail engagement feature |
US11529241B2 (en) | 2010-09-23 | 2022-12-20 | DePuy Synthes Products, Inc. | Fusion cage with in-line single piece fixation |
US20120078373A1 (en) | 2010-09-23 | 2012-03-29 | Thomas Gamache | Stand alone intervertebral fusion device |
US9402732B2 (en) | 2010-10-11 | 2016-08-02 | DePuy Synthes Products, Inc. | Expandable interspinous process spacer implant |
US8814905B2 (en) | 2010-11-23 | 2014-08-26 | Depuy Mitek, Llc | Surgical filament snare assemblies |
US8821543B2 (en) | 2010-12-23 | 2014-09-02 | Depuy Mitek, Llc | Adjustable anchor systems and methods |
US9345468B2 (en) | 2010-11-23 | 2016-05-24 | Medos International Sárl | Surgical filament snare assemblies |
WO2012088496A2 (en) | 2010-12-23 | 2012-06-28 | Depuy Mitek, Inc. | Adjustable anchor systems and methods |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
AU2012231108B2 (en) | 2011-03-22 | 2015-10-22 | DePuy Synthes Products, LLC | Universal trial for lateral cages |
US8956523B2 (en) * | 2011-09-06 | 2015-02-17 | Rohm And Haas Electronic Materials Llc | Metal plating compositions and methods |
US9248028B2 (en) | 2011-09-16 | 2016-02-02 | DePuy Synthes Products, Inc. | Removable, bone-securing cover plate for intervertebral fusion cage |
US8535350B2 (en) | 2011-09-28 | 2013-09-17 | Depuy Mitek, Llc | Knotless suture anchor |
US20130085528A1 (en) | 2011-09-30 | 2013-04-04 | Depuy Mitek, Inc. | Knotless suture anchor |
US9271836B2 (en) | 2012-03-06 | 2016-03-01 | DePuy Synthes Products, Inc. | Nubbed plate |
US9226764B2 (en) | 2012-03-06 | 2016-01-05 | DePuy Synthes Products, Inc. | Conformable soft tissue removal instruments |
US8790370B2 (en) | 2012-03-30 | 2014-07-29 | Depuy Mitek, Llc | Surgical filament assemblies |
US8894684B2 (en) | 2012-05-07 | 2014-11-25 | Medos International Sàrl | Systems, devices, and methods for securing tissue using a suture having one or more protrusions |
US9060764B2 (en) | 2012-05-07 | 2015-06-23 | Medos International Sàrl | Systems, devices, and methods for securing tissue |
US9345567B2 (en) | 2012-05-07 | 2016-05-24 | Medos International Sàrl | Systems, devices, and methods for securing tissue using snare assemblies and soft anchors |
US9060763B2 (en) | 2012-05-07 | 2015-06-23 | Medos International Sàrl | Systems, devices, and methods for securing tissue |
US9763655B2 (en) | 2012-09-20 | 2017-09-19 | Medos International Sarl | Systems, devices, and methods for securing tissue using hard anchors |
US10182921B2 (en) | 2012-11-09 | 2019-01-22 | DePuy Synthes Products, Inc. | Interbody device with opening to allow packing graft and other biologics |
US10022245B2 (en) | 2012-12-17 | 2018-07-17 | DePuy Synthes Products, Inc. | Polyaxial articulating instrument |
US9271716B2 (en) | 2012-12-27 | 2016-03-01 | Medos International Sàrl | Surgical constructs and methods for securing tissue |
US9522070B2 (en) | 2013-03-07 | 2016-12-20 | Interventional Spine, Inc. | Intervertebral implant |
US10123862B2 (en) | 2013-03-14 | 2018-11-13 | Ethicon, Inc. | Randomly uniform three dimensional tissue scaffold of absorbable and non-absorbable materials |
US9352071B2 (en) | 2013-03-14 | 2016-05-31 | Ethicon, Inc. | Method of forming an implantable device |
US9737293B2 (en) | 2013-03-15 | 2017-08-22 | Medos International Sàrl | Surgical constructs with collapsing suture loop and methods for securing tissue |
US10463471B2 (en) | 2013-07-18 | 2019-11-05 | Medos International Sarl | Methods and devices for positioning and securing ligament grafts |
RU2699811C1 (en) | 2014-03-07 | 2019-09-11 | Айконлаб Инк. | Multipurpose implant with specified surface structure for soft tissue reconstruction |
US10588732B2 (en) | 2014-03-07 | 2020-03-17 | IconLab USA, Inc. | Multipurpose implant with modeled surface structure for soft tissue reconstruction |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US11426290B2 (en) | 2015-03-06 | 2022-08-30 | DePuy Synthes Products, Inc. | Expandable intervertebral implant, system, kit and method |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
CN109310743A (en) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | Glucagon receptor selectivity polypeptide and its application method |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
WO2018002715A2 (en) | 2016-06-28 | 2018-01-04 | Eit Emerging Implant Technologies Gmbh | Expandable and angularly adjustable articulating intervertebral cages |
WO2018002711A2 (en) | 2016-06-28 | 2018-01-04 | Eit Emerging Implant Technologies Gmbh | Expandable, angularly adjustable intervertebral cages |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
US10398563B2 (en) | 2017-05-08 | 2019-09-03 | Medos International Sarl | Expandable cage |
US10940016B2 (en) | 2017-07-05 | 2021-03-09 | Medos International Sarl | Expandable intervertebral fusion cage |
US10966843B2 (en) | 2017-07-18 | 2021-04-06 | DePuy Synthes Products, Inc. | Implant inserters and related methods |
US11045331B2 (en) | 2017-08-14 | 2021-06-29 | DePuy Synthes Products, Inc. | Intervertebral implant inserters and related methods |
US11446156B2 (en) | 2018-10-25 | 2022-09-20 | Medos International Sarl | Expandable intervertebral implant, inserter instrument, and related methods |
US11426286B2 (en) | 2020-03-06 | 2022-08-30 | Eit Emerging Implant Technologies Gmbh | Expandable intervertebral implant |
US11850160B2 (en) | 2021-03-26 | 2023-12-26 | Medos International Sarl | Expandable lordotic intervertebral fusion cage |
US11752009B2 (en) | 2021-04-06 | 2023-09-12 | Medos International Sarl | Expandable intervertebral fusion cage |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4689424A (en) * | 1981-08-06 | 1987-08-25 | Ethicon, Inc. | Radiation sterilizable absorbable polymeric materials and methods for manufacturing the same |
US4464929A (en) * | 1981-09-21 | 1984-08-14 | William M. Willis, Sr. | Tire cap pressure gauge |
JPH0233052B2 (en) * | 1982-06-28 | 1990-07-25 | Kawaken Fuainkemikaru Kk | SHUKUGOJUGOTAINOSEIZOHOHO |
US4510295A (en) * | 1983-01-20 | 1985-04-09 | Ethicon, Inc. | Absorbable polymers of substituted benzoic acid |
US4440922A (en) * | 1983-04-13 | 1984-04-03 | Eastman Kodak Co. | Polyester containers having improved gas barrier properties |
US4546152A (en) * | 1984-03-07 | 1985-10-08 | Ethicon, Inc. | Poly(p-dioxanone) polymers having improved radiation resistance |
DE3432320A1 (en) * | 1984-09-03 | 1986-03-13 | Behringwerke Ag, 3550 Marburg | CIS-PLATINUM COMPLEXES WITH A PENTAERYTHRITE DERIVATIVE AS A LIGAND, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENT CONTAINING THESE COMPOUNDS |
US4552948A (en) * | 1985-03-29 | 1985-11-12 | Eastman Kodak Company | Polyester resins capable of forming containers having improved gas barrier properties |
GB8516618D0 (en) * | 1985-07-01 | 1985-08-07 | Ici Plc | Polyether polyols |
DE3901279A1 (en) * | 1989-01-18 | 1990-07-19 | Hoechst Ag | USE OF POLYAMIDOAMINES AS HARDENERS FOR EPOXY RESINS AND CONTAINABLE MIXTURES CONTAINING THEM |
US4963641A (en) * | 1989-05-30 | 1990-10-16 | Eastman Kodak Company | Polyester with improved gas barrier properties from cycloalkylidene bis (p-phenyleneoxy) diacetic acid |
US5349028A (en) * | 1992-05-11 | 1994-09-20 | Showa Highpolymer Co., Ltd. | Polyester fibers |
US5597579A (en) * | 1995-03-06 | 1997-01-28 | Ethicon, Inc. | Blends of absorbable polyoxaamides |
US5464929A (en) * | 1995-03-06 | 1995-11-07 | Ethicon, Inc. | Absorbable polyoxaesters |
-
1996
- 1996-03-05 US US08/611,532 patent/US5597579A/en not_active Expired - Lifetime
- 1996-08-07 US US08/695,158 patent/US5645850A/en not_active Expired - Lifetime
-
1997
- 1997-03-04 CA CA002199079A patent/CA2199079A1/en not_active Abandoned
- 1997-03-04 AU AU15075/97A patent/AU1507597A/en not_active Abandoned
- 1997-03-04 EP EP97301423A patent/EP0794211B1/en not_active Expired - Lifetime
- 1997-03-04 ZA ZA971868A patent/ZA971868B/en unknown
- 1997-03-04 DE DE69734905T patent/DE69734905T2/en not_active Expired - Fee Related
- 1997-03-05 MX MX9701690A patent/MX9701690A/en unknown
- 1997-03-05 CN CN97110090A patent/CN1167126A/en active Pending
- 1997-03-05 JP JP9065569A patent/JPH107793A/en active Pending
- 1997-03-05 BR BR9701197A patent/BR9701197A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1167126A (en) | 1997-12-10 |
ZA971868B (en) | 1999-01-22 |
DE69734905T2 (en) | 2006-09-14 |
JPH107793A (en) | 1998-01-13 |
EP0794211A2 (en) | 1997-09-10 |
EP0794211B1 (en) | 2005-12-21 |
DE69734905D1 (en) | 2006-01-26 |
US5597579A (en) | 1997-01-28 |
US5645850A (en) | 1997-07-08 |
MX9701690A (en) | 1998-04-30 |
EP0794211A3 (en) | 1998-04-15 |
BR9701197A (en) | 1998-12-15 |
AU1507597A (en) | 1997-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5597579A (en) | Blends of absorbable polyoxaamides | |
EP0771832B1 (en) | Blends of absorbable polyoxaesters containing amines and/or amido groups | |
US5607687A (en) | Polymer blends containing absorbable polyoxaesters | |
US5595751A (en) | Absorbable polyoxaesters containing amines and/or amido groups | |
EP0731123B1 (en) | Absorbable polyoxaesters | |
US5618552A (en) | Absorbable polyoxaesters | |
US6458385B2 (en) | Hydrogels containing absorbable polyoxaamides | |
US5700583A (en) | Hydrogels of absorbable polyoxaesters containing amines or amido groups | |
US6074660A (en) | Absorbable polyoxaesters containing amines and/ or amido groups | |
US6100346A (en) | Copolymers of polyoxaamides | |
CA2220351A1 (en) | Hydrogels of absorbable polyoxaesters | |
EP1223951A1 (en) | Method of preventing adhesions with absorbable polyoxaesters | |
US5844017A (en) | Prepolymers of absorbable polyoxaesters containing amines and/or amido groups | |
EP0771849B1 (en) | Polymer blends containing polyoxaesters and lactone polymers | |
CA2189521C (en) | Polymer blends containing absorbable polyoxaesters | |
AU745743B2 (en) | Blends containing absorbable polyoxaamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |